研究等業績 - その他 - 髙橋 直人
-
c-FOS Confers Stem Cell-like Features to Multiple Myeloma Cells in a Bone Marrow Microenvironment
Osada N.
Cells ( Cells ) 14 ( 7 ) 2025年04月
-
症例からひもとく疾患 慢性骨髄性白血病
藤岡 優樹, 永沼 綾子, 齊藤 由紀子, 植木 重治, 髙橋 直人
検査と技術 ( 株式会社医学書院 ) 53 ( 4 ) 446 - 452 2025年04月
-
Kondo H.
Therapeutic Innovation and Regulatory Science ( Therapeutic Innovation and Regulatory Science ) 59 ( 1 ) 71 - 79 2025年01月
-
Kondo T.
Cancer ( Cancer ) 131 ( 1 ) 2025年01月
-
Kumagai Takuya, Saito Masaya, Sato Takahiko, Inoue Junichi, Ishikawa Norihisa, Ono Tsuyoshi, Kono Michihiro, Takahashi Naoto
Internal Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 2025年
<p>We herein report a case of cutaneous squamous cell carcinoma (SCC) characterized by paraneoplastic hypercalcemia-leukocytosis syndrome. The patient presented with systemic symptoms, including anorexia, a fever, and a tumoral lesion on the upper arm. Laboratory test results revealed hypercalcemia and leukocytosis. A tissue biopsy confirmed SCC, and further investigation revealed elevated parathyroid hormone-related protein (PTHrP) and granulocyte-colony stimulating factor (G-CSF) levels. Immunostaining demonstrated G-CSF production by the tumor cells. Radiation therapy was administered, which improved leukocytosis and decreased G-CSF and PTHrP levels. Through a case report and literature review, we explored the clinical characteristics of tumors that produce G-CSF and PTHrP. </p>
-
Imamura K.
BMJ Open ( BMJ Open ) 14 ( 10 ) 2024年10月
-
膜性腎症を合併し多彩な自己抗体陽性を認めた全身性強皮症
橋本 眞子, 阿部 史人, 齋藤 綾乃, 坂口 舞, 金澤 達郎, 齋藤 雅也, 高橋 直人
日本リウマチ学会北海道・東北支部学術集会抄録集 ( (一社)日本リウマチ学会-北海道・東北支部 ) 34回 84 - 84 2024年10月
-
LINC00887はHDAC3との結合を介して多発性骨髄腫細胞の薬剤耐性を誘導する
長田 直希, 松岡 紗恵, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 1 2024年10月
-
SETD7はt(11;14)陽性多発性骨髄腫に対する新たな治療標的分子となる
松岡 紗恵, 長田 直希, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 4 2024年10月
-
TFR後の晩期再発は免疫の調節不全を背景にしている
藤岡 優樹, 植木 重治, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 5 2024年10月
-
Minami Y.
International Journal of Hematology ( International Journal of Hematology ) 120 ( 3 ) 305 - 313 2024年09月
-
ネフローゼ症候群を呈する巣状分節性糸球体硬化症を併発した糖原病Ia型の一例
坂口 舞, 齋藤 雅也, 橋本 眞子, 齋藤 綾乃, 阿部 史人, 野口 篤子, 金澤 達郎, 熊谷 拓哉, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 66 ( 6-E ) 953 - 953 2024年09月
-
Takahashi N.
Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 54 ( 8 ) 930 - 938 2024年08月
-
保存期CKDにおける赤血球分布幅とESA初期治療抵抗性の関連
金澤 達郎, 齋藤 雅也, 齋藤 綾乃, 阿部 史人, 橋本 眞子, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 66 ( 4 ) 630 - 630 2024年06月
-
糖尿病性腎病腎組織におけるToll-like receptor 4発現と腎予後の検討
齋藤 綾乃, 阿部 史人, 齋藤 雅也, 金澤 達郎, 橋本 眞子, 坂口 舞, 中山 隆弘, 大谷 浩, 澤村 昌人, 奥山 慎, 政井 理恵, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 66 ( 4 ) 673 - 673 2024年06月
-
Hidaka M.
Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 54 ( 2 ) 153 - 159 2024年02月
-
7．慢性骨髄性白血病の治療の進歩
髙橋 直人
日本内科学会雑誌 ( 一般社団法人 日本内科学会 ) 113 ( Suppl ) 120a - 120a 2024年02月
-
Sato H.
International Journal of Clinical Oncology ( International Journal of Clinical Oncology ) 29 ( 4 ) 481 - 492 2024年
-
クローン病の治療中に発症し臍帯血移植が奏効した化学療法抵抗性<i>γδ</i>型肝脾T細胞リンパ腫
齊藤 暉人, 奈良 美保, 藤島 崇嗣, 黒木 航, 山下 鷹也, 小林 敬宏, 池田 翔, 北舘 明宏, 亀岡 吉弘, 高橋 直人
臨床血液 ( 一般社団法人 日本血液学会 ) 65 ( 1 ) 41 - 46 2024年
<p>症例21歳男性。Crohn病のためinfliximab，azathioprineによる治療を受けていたが6年後，発熱，LDH 2,473 U/<i>l</i>，血小板低下，肝脾腫を認めた。骨髄生検と肝生検でCD4，CD56，TCR<i>γδ</i>陽性，CD8陰性の異型細胞を認め，肝脾T細胞リンパ腫（hepatosplenic T-cell lymphoma, HSTCL）と診断した。CHOP療法，dose-adjusted-EPOCH療法後に非寛解状態で骨髄破壊的前処置による臍帯血移植を行った。退院前造影CTで肝脾腫縮小，LDH 165 U/<i>l</i>，血小板18万/µ<i>l</i>と正常化を認めday117に退院した。HSTCLは脾臓内のV<i>δ</i>1遺伝子変異を伴う未熟な<i>γδ</i>T細胞をカウンターパートとする腫瘍であり，発症には免疫不全状態の関与が示唆されており予後は不良である。Azathioprineで治療された炎症性腸疾患患者はリンパ増殖性疾患リスクが増加することが知られており，本症例もCrohn病に対する免疫抑制剤の使用により腸管上皮に存在する<i>γδ</i>細胞が悪性化した可能性がある。化学療法抵抗性であったが早期の臍帯血移植で寛解を達成し，長期予後を期待している。</p>
-
Arai H.
International Journal of Hematology ( International Journal of Hematology ) 121 ( 3 ) 378 - 387 2024年
-
Takahashi N.
International Journal of Hematology ( International Journal of Hematology ) 121 ( 1 ) 5 - 38 2024年
-
Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto
Cancer Chemotherapy and Pharmacology ( Springer Nature ) 2024年
-
Cortes J.E.
Future Oncology ( Future Oncology ) 18 ( 38 ) 4161 - 4170 2023年12月
-
経口薬で白血病を治す－CMLに対する分子標的療法の挑戦
高橋 直人
日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 ) 33 ( 0 ) 4 - 4 2023年11月
-
t(4;14)陽性多発性骨髄腫に対するMMSET阻害剤
松岡 紗恵, 菊池 次郎, 長田 直希, 窪田 浩一, 喜久里 貢, 小山 裕雄, 菊地 正樹, 安井 寛, 池田 翔, 高橋 直人, 梅原 崇史, 仲宗根 秀樹, 古川 雄祐
日本血液学会学術集会 ( (一社)日本血液学会 ) 85回 44 - 44 2023年10月
-
Clinical Course of a Rare Epstein-Barr Virus-Associated Smooth Muscle Tumor and Its Genomic Analysis
Miyahara J.
Case Reports in Oncology ( Case Reports in Oncology ) 16 ( 1 ) 577 - 584 2023年08月
Epstein-Barr virus (EBV) can rarely induce smooth muscle tumors (SMTs). A 20-year-old female patient underwent kidney transplantation for renal failure. Since then, she has been treated with immunosuppressants, including a calcineurin inhibitor, tacrolimus, and prednisolone, owing to the immunological rejection. Three years later, she developed large liver tumors (diameter >5 cm) and multiple small lung tumors that were identified as EBV-SMTs based on the results of liver biopsy/histopathology. No intervention was performed except for the addition of a mammalian target of the rapamycin inhibitor, everolimus, which inhibits both immune reaction and SMT growth. Finally, after 8 years, the transplanted kidney became nonfunctional, and immunosuppressant administration became unnecessary as urinary dialysis was started. Under these circumstances, SMT growth was observed despite the absence of immunosuppressant administration. Three months after the cessation of the immunosuppressants, EBV-SMTs in the liver and lungs shrank slightly. To the best of our knowledge, this is the first report on the genomic profile of this rare tumor. The clinical course of our patient indicates that EBV can induce SMTs, and immunological suppression of EBV may inhibit the activity of these tumors.
-
Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation.
Kazuaki Teshima, Sho Ikeda, Ko Abe, Masahiro Yamada, Naoto Takahashi
Cureus 15 ( 7 ) e42215 2023年07月
A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes.
-
保存期CKDにおけるESA初期治療抵抗性と予後に関する検討
金澤 達郎, 齋藤 雅也, 齋藤 綾乃, 阿部 史人, 加賀 一, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 65 ( 3 ) 294 - 294 2023年05月
-
糖尿病性腎臓病腎組織におけるToll-like receptor 4発現と病理学的検討
齋藤 綾乃, 阿部 史人, 齋藤 雅也, 加賀 一, 金澤 達郎, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 65 ( 3 ) 317 - 317 2023年05月
-
長田 直希, 菊池 次郎, 安井 寛, 池田 翔, 松岡 紗恵, 高橋 直人, 古川 雄祐
International Journal of Myeloma ( (一社)日本骨髄腫学会 ) 13 ( 3 ) 136 - 136 2023年05月
-
Onishi Y.
International Journal of Hematology ( International Journal of Hematology ) 117 ( 5 ) 738 - 747 2023年
-
Hosono N.
Cancer Science ( Cancer Science ) 114 ( 5 ) 2098 - 2108 2023年
-
難治性食道狭窄を来した同種造血幹細胞移植後の食道粘膜類天疱瘡
藤田 菜々子, 山下 鷹也, 阿部 史人, 奈良 美保, 吉岡 智子, 古賀 浩嗣, 石井 文人, 高橋 直人
臨床血液 ( 一般社団法人 日本血液学会 ) 64 ( 2 ) 107 - 112 2023年
<p>40代女性。AML再発に対し血縁者間HLA半合致移植を施行。移植後day59に食道狭窄症を発症した。GVHDと診断し免疫抑制療法中は定期的な食道拡張術で安定していたが，AML再々発に伴い免疫抑制剤を中止すると食道狭窄の増悪を認めた。食道粘膜は易出血性・易剥離性であり，生検組織で剥脱した重層扁平上皮と上皮下の肉芽組織との離開を認めた。蛍光抗体直接法で基底膜部へのIgGとIgAの線状沈着を認め，蛍光抗体間接法ではIgG陰性，IgAが表皮側で陽性，BP180のC末端部位リコンビナント蛋白を用いた免疫ブロット法ではIgG，IgAが陽性であり，抗BP180型粘膜類天疱瘡と診断した。同種移植後の類天疱瘡はGVHDにより表皮の基底細胞が傷害され基底膜部蛋白が露出し，抗原提示されることにより生じると考えられている。本症例も同様の機序と考えられ，典型的なGVHDと異なる症例では詳細な組織診断が重要である。</p>
-
Ono T.
International Journal of Hematology ( International Journal of Hematology ) 116 ( 6 ) 871 - 882 2022年12月
Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dose of 400 mg once daily in Japanese patients (n = 60) with newly diagnosed CP-CML. The minimum follow-up period was 3 years and median duration of treatment was 35.9 months. At study completion, 60% of patients were still on treatment. Cumulative rates of major molecular response (MMR), molecular response4 (MR4), and MR4.5 at any time were 70.0%, 53.3%, and 48.3%, respectively. No patient who achieved MMR or MR4 had a confirmed loss of response. No patient experienced on-treatment transformation to accelerated/blast phase or died within 28 days of the last bosutinib dose. Any-grade treatment-emergent adverse events (TEAEs) occurred in 100% (grade ≥ 3: 81.7%) of patients. The most common TEAEs were diarrhea (86.7%), increased alanine aminotransferase (55.0%), and increased aspartate aminotransferase (46.7%). No new safety signals emerged during the follow-up period. Bosutinib continues to demonstrate a favorable benefit/risk profile and is an important treatment option for Japanese patients with newly diagnosed CP-CML. Optimal management of TEAEs during initial treatment with bosutinib should be prioritized.Trial Registration: ClinicalTrials.gov ID: NCT03128411.
-
Kaga H.
Clinical Proteomics ( Clinical Proteomics ) 19 ( 1 ) 2022年12月
-
Evaluation of protein production in rice seedlings under dark conditions
Watanabe A.
Scientific Reports ( Scientific Reports ) 12 ( 1 ) 2022年12月
-
Imamura K.
eClinicalMedicine ( eClinicalMedicine ) 53 2022年11月
-
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
今村 恵子, 和泉 唯信, 永井 真貴子, 西山 和利, 渡辺 保裕, 花島 律子, 江川 斉宏, 綾木 孝, 沖 良祐, 藤田 浩司, 魚住 龍史, 森永 明子, 廣橋 朋子, 藤井 陽介, 山本 拓也, 建部 陽嗣, 徳田 隆彦, 高橋 直人, 森田 智視, 髙橋 良輔, 井上 治久
eClinicalMedicine ( Elsevier BV ) 53 2022年11月
[Background] Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease caused by the loss of motor neurons, and development of effective medicines is urgently required. Induced pluripotent stem cell (iPSC)-based drug repurposing identified the Src/c-Abl inhibitor bosutinib, which is approved for the treatment of chronic myelogenous leukemia (CML), as a candidate for the molecular targeted therapy of ALS. [Methods] An open-label, multicentre, dose-escalation phase 1 study using a 3 + 3 design was conducted in 4 hospitals in Japan to evaluate the safety and tolerability of bosutinib in patients with ALS. Furthermore, the exploratory efficacy was evaluated using Revised ALS Functional Rating Scale (ALSFRS-R), predictive biomarkers including plasma neurofilament light chain (NFL) were explored, and single-cell RNA sequencing of iPSC-derived motor neurons was conducted. Patients, whose total ALSFRS-R scores decreased by 1–3 points during the 12-week, received escalating doses starting from 100 mg quaque die (QD) up to 400 mg QD based on dose-limiting toxicity (DLT) occurrence, and all participants who received one dose of the study drug were included in the primary analysis. This trial is registered with ClinicalTrials.gov, NCT04744532, as Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic Lateral Sclerosis Medicine (iDReAM) study. [Findings] Between March 29, 2019 and May 7, 2021, 20 patients were enrolled, 13 of whom received bosutinib treatment and 12 were included in the safety and efficacy analyses. No DLTs were observed up to 300 mg QD, but DLTs were observed in 3/3 patients of the 400 mg QD cohort. In all patients receiving 100 mg–400 mg, the prevalent adverse events (AEs) were gastrointestinal AEs in 12 patients (92.3%), liver function related AEs in 7 patients (53.8%), and rash in 3 patients (23.1%). The safety profile was consistent with that known for CML treatment, and ALS-specific AEs were not observed. A subset of patients (5/9 patients) was found to respond well to bosutinib treatment over the 12-week treatment period. It was found that the treatment-responsive patients could be distinguished by their lower levels of plasma NFL. Furthermore, single-cell RNA sequencing of iPSC-derived motor neurons revealed the pathogenesis related molecular signature in patients with ALS showing responsiveness to bosutinib. [Interpretation] This is the first trial of a Src/c-Abl inhibitor, bosutinib, for patients with ALS. The safety and tolerability of bosutinib up to 300 mg, not 400 mg, in ALS were described, and responsiveness of patients on motor function was observed. Since this was an open-label trial within a short period with a limited number of patients, further clinical trials will be required.
-
Kuroki W.
International Journal of Hematology ( International Journal of Hematology ) 116 ( 5 ) 712 - 722 2022年11月
Despite the introduction of rituximab-containing regimens, approximately 20% of patients with follicular lymphoma (FL) still experience progression of disease within 24 months (POD24) and have poor overall survival. Therefore, a more accurate risk assessment tool is required. We investigated the predictive value of two new volume-based parameters determined from baseline 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT), baseline total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG), in 45 patients with high-tumor-burden FL who underwent baseline PET/CT. We observed that high TMTV, high TLG, and poor initial treatment response (less than complete [metabolic] response [non-CR/CMR] at the end of induction therapy) independently predicted poor PFS. Notably, POD24-positive patients were more common in the high-TLG group than in the high-TMTV group, which suggests that TLG is a stronger predictor of outcomes than TMTV. Combining baseline TLG and initial treatment response showed that patients with both high TLG and non-CR/CMR experienced significantly poorer outcomes, with a 2 year PFS of 0% (hazard ratio 60.39, P = 0.000002). This combination had 56% sensitivity and 100% specificity for detecting patients who would experience POD24. Baseline TLG and initial treatment response can precisely identify patients at high risk of POD24.
-
膜性腎症・V型ループス腎炎におけるExostosin1/Exostosin2の検討
今泉 ちひろ, 橋本 眞子, 阿部 史人, 加賀 一, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 高橋 直人
秋田腎不全研究会誌 ( 秋田腎不全研究会 ) 25 33 - 37 2022年11月
-
単純型血漿交換とリツキシマブが有効であったIgM・IgG型温式抗体を有するEvans症候群
藤田 菜々子, 亀岡 吉弘, 齋藤 綾乃, 齋藤 雅也, 藤岡 優樹, 鵜生川 久美, 奈良 美保, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 63 ( 11 ) 1590 - 1590 2022年11月
-
膜性腎症・V型ループス腎炎におけるExostosin1/Exostosin2の検討
今泉 ちひろ, 橋本 眞子, 阿部 史人, 加賀 一, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 高橋 直人
秋田腎不全研究会誌 ( 秋田腎不全研究会 ) 25 33 - 37 2022年11月
当院と関連施設で1990～2020年に腎生検を施行された症例のうち、膜性腎症と診断された374例と、V型ループス腎炎と診断された66例を対象とし、Exostosin(EXT)1/2の検出率について調査した。結果、膜性腎症患者のうちPLA2R陽性例(98例)でEXT1/2が検出されたものは1例もなく、PLA2R陰性例(174例)ではEXT1/2が4例(2%)で検出された。ループス腎炎患者では19例(29%)でEXT1/2が検出された。ループス腎炎患者をEXT1/2陽性群と陰性群に分け、ネフローゼ症候群の合併率、細胞増殖性病変の合併率、腎障害の程度、抗ds-DNA抗体陽性率、低補体血症の合併率などについて群間比較した結果、いずれも有意差は認められなかった。
-
Natsuki Fukuda, Takahiro Kobayashi, Honami Sato, Yumiko Akamine, Naoto Takahashi, Masatomo Miura
Journal of Chromatographic Science ( Oxford University Press (OUP) ) 62 ( 1 ) 58 - 64 2022年10月
Abstract
A simple, highly sensitive and specific method based on high-performance liquid chromatography (HPLC) with ultraviolet detection was developed for the measurement of venetoclax concentrations in plasma samples. The chromatographic method employed a mobile phase of acetonitrile: 0.5% KH2PO4 (pH 3.5) (80/20, v/v) on a CAPCELL PAK C18 UG120 column at a flow rate of 0.5 mL/min. The quantitative method was validated based on standards described in “Bioanalytical Method Validation: Guidance for Industry” published by the US Food and Drug Administration. The separation of venetoclax and the internal standard R051012 was satisfactory, and the chromatograms were free of interfering peaks from the biological matrix. The intra- and inter-day coefficients of variation for venetoclax assays were &lt;12.9%, whereas intra- and inter-day accuracies were within 13.6%. Only 100 μL of human plasma was required to detect a lower limit of quantification of 10 ng/mL for venetoclax. The recoveries of venetoclax extracted with an Oasis HLB cartridge were between 81 and 85%. The developed HPLC method was successfully applied to the determination of venetoclax concentrations in plasma of acute myeloid leukemia patients taking venetoclax. The degree of drug interactions between venetoclax and CYP3A4 inhibitors can be determined by this HPLC assay. -
コロナワクチン2回目接種直後にIgA血管炎を発症した一例
和田 邦宏, 澤村 昌人, 橋本 眞子, 阿部 史人, 加賀 一, 斉藤 綾乃, 斉藤 雅也, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 64 ( 6-E ) 545 - 545 2022年10月
-
Hughes T.P.
Clinical Lymphoma, Myeloma and Leukemia ( Clinical Lymphoma, Myeloma and Leukemia ) 22 S297 - S298 2022年10月
-
秋田県腎生検症例におけるExostosin1/Exostosin2の検討
今泉 ちひろ, 阿部 史人, 加賀 一, 齋藤 綾乃, 齋藤 雅也, 高橋 直人
日本臨床免疫学会総会プログラム・抄録集 ( (一社)日本臨床免疫学会 ) 50回 103 - 103 2022年10月
-
Nara M.
Clinical Nephrology ( Clinical Nephrology ) 98 ( 3 ) 135 - 146 2022年09月
Monoclonal immunoglobulin (MIg)-associated glomerular diseases with non-organized deposits are rare disorders. They have recently been categorized into light chain deposit disease (LCDD), light and heavy chain deposit disease (LHCDD), heavy chain deposit disease (HCDD), proliferative glomerulonephritis with MIg deposits (PGNMID) and its light chain only variant (PGNMID-LC), and membranous glomerulopathy with light chain-restricted deposits (MG-LC). In our Japanese cohort of more than 9,500 patients who underwent renal biopsy (1979 - 2020), we evaluated clinicopathological features and long-term outcomes in 38 patients with MIg-associated glomerular diseases with non-organized deposits: LCDD (n = 9), LHCDD (n = 8), HCDD (n = 5), PGNMID-membranoproliferative glomerulonephritis (MPGN) (n = 7), PGNMID-LC (n = 2), and MG-LC (n = 7). In patients with LCDD, a low estimated glomerular filtration rate (eGFR) at biopsy, a high detection rate of urinary MIgs, a high incidence rate of multiple myeloma, and sever tubulointerstitial and vascular lesions were significant clinicopathological characteristics. Median duration of follow-up in each group was 42 - 114 months. Most patients were treated with steroid-based therapy. Patients with LCDD, LHCDD, HCDD, and MG-LC were recently treated with bortezomib-based therapy. Renal survival rate was significantly shorter for LCDD than of PGNMID and MG-LC. Patient survival rate was significantly longer for MG-LC than HCDD and PGNMID. Major causes of death were pulmonary and cardiovascular complications. Among disease groups, significant differences were observed in eGFR at biopsy, detection rates of urinary MIgs, incidence rates of multiple myeloma, severities of tubulointerstitial and vascular lesions, and long-term outcomes.
-
Sato H.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 90 ( 3 ) 279 - 284 2022年09月
PURPOSE: Leukemic stem cells in acute myeloid leukemia (AML) express high B cell lymphoma 2 (BCL2) levels, which contribute to leukemic cell survival and resistance to therapy. Venetoclax-a BCL-2 inhibitor-is indicated for the treatment of AML, which may also target leukemic stem cells; however, it is only available as a tablet. There are no reports of venetoclax use in patients who cannot take oral drugs; therefore, the efficacy, safety, and pharmacokinetics (PK) of venetoclax administered through a gastrostomy tube is unknown. CASE PRESENTATION: We report, for the first time, a case of relapsed Japanese AML patient treated with crushed venetoclax tablets through a percutaneous endoscopic gastrostomy (PEG) tube because of esophageal stricture due to complications of stem cell transplantation. The patient was also taking posaconazole and clarithromycin concomitantly. We evaluated the plasma concentrations of venetoclax administered through a PEG tube. Time to maximum concentration, maximum plasma concentration, and the area under the plasma concentration-time curve were similar to the previously reported PK parameters after oral administration of intact venetoclax tablets in Japanese patients with AML. The clinical course passed safely without the occurrence of unexpected adverse events during the administration of crushed venetoclax tablets in combination with azacitidine. CONCLUSIONS: The PK parameters of the crushed administered venetoclax via PEG tube was similar to the previously reported PK parameters of the orally administered venetoclax. Therefore, administration of crushed venetoclax tablets through a PEG tube could be an alternate route for patients who have difficulty with oral administration.
-
Jiro Kikuchi, Nobuyuki Kodama, Masataka Takeshita, Sho Ikeda, Takahiro Kobayashi, Yoshiaki Kuroda, Michihiro Uchiyama, Naoki Osada, Bjarne Bogen, Hiroshi Yasui, Naoto Takahashi, Akiyoshi Miwa, Yusuke Furukawa
Blood Advances ( American Society of Hematology ) 7 ( 4 ) 508 - 524 2022年08月
Extramedullary disease (EMD) is known to be associated with chemoresistance and poor prognosis in multiple myeloma (MM); however, the mechanisms of its development are not fully understood. Elucidating the mechanism of EMD development and its therapeutic targeting would greatly contribute to further improvement of treatment outcome in MM patients. Here, we show that bone marrow stroma cell-derived hyaluronan elicits homophilic interactions of MM cells by binding to surface CD44, especially long-stretch variants, under physiological shear stress and generates cell clusters that might develop into EMD. We recapitulated the development of EMD via administration of hyaluronan in a syngeneic murine MM model in a CD44-dependent manner. Hyaluronan-induced MM cell clusters exhibited the specific resistance to proteasome inhibitors (PIs) in vitro and in murine models via γ-secretase-mediated cleavage of the intracellular domains of CD44, which in turn transactivated PI resistance-inducible genes. Treatment of hyaluronan-injected mice with anti-CD44 antibody or γ-secretase inhibitors readily suppressed the development of EMD from transplanted MM cells and significantly prolonged the survival of recipients by overcoming PI resistance. The hyaluronan-CD44 axis represents a novel pathway to trigger EMD development and could be a target of the prediction, prevention, and treatment of EMD in MM patients.
-
Saito M.
Clinical and Experimental Nephrology ( Clinical and Experimental Nephrology ) 26 ( 8 ) 760 - 769 2022年08月
BACKGROUND: We determined the usefulness and prognostic ability of the renal risk score (RRS), proposed in Europe, for Japanese patients with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN) and high myeloperoxidase (MPO)-ANCA positivity; these aspects remain to be verified. METHODS: This retrospective study was conducted on 86 Japanese patients with new, biopsy-confirmed AAGN. We calculated the RRS and analyzed the relationship between this classification, and clinicopathological features and prognosis. We also compared the predictive values between RRS for endpoints including renal death and conventional prognostic tools for patients with AAGN. RESULTS: There were 33, 37, and 16 patients in the low-, medium-, and high-risk groups, respectively. All patients were MPO-ANCA positive. The median follow-up period was 33 months; 16 (18.6%) patients progressed to end-stage renal disease (ESRD). In the high-risk group, 9/16 (56.3%) patients progressed to ESRD, and renal prognosis was significantly poorer than that in other groups (low-risk group, P < 0.001; medium-risk group, P = 0.004). In Cox multivariate regression analysis, RRS was an independent, poor renal prognostic factor (hazard ratio 5.22; 95% confidence interval 2.20-12.40; P < 0.001). The receiver-operating characteristic curves of the RRS for each endpoint were comparable with those of the 2010 histological classification and those of the severity classification of Japanese rapidly progressive glomerulonephritis. CONCLUSIONS: This is the first study to report the usefulness of the RRS for predicting renal outcomes among Japanese patients with AAGN. Our predictive value of the RRS was comparable with that of conventional prognostic tools.
-
Abe F.
Modern Rheumatology Case Reports ( Modern Rheumatology Case Reports ) 6 ( 2 ) 278 - 281 2022年06月
IgG4-related disease (IgG4-RD) involves multiple organs, including the lungs and central nervous system. Lung lesions are frequently reported as mass lesions or non-specific interstitial pneumonia, whereas organizing pneumonia (OP) due to IgG4-RD is rare. Furthermore, limited information is currently available on hypertrophic pachymeningitis (HP). We herein report a case of IgG4-RD complicated with OP and HP. The diagnosis was confirmed based on the serum concentration of IgG4 and the results of salivary gland and transbronchial lung biopsies. HP did not respond to steroid monotherapy and was also resistant to rituximab and intravenous cyclophosphamide; however, the combination therapy of methotrexate and dexamethasone was effective.
-
脾臓浸潤による非外傷性脾破裂をきたし剖検で確定診断した血管内大細胞型B細胞リンパ腫
黒木 航, 小林 敬宏, 馬越 通信, 北舘 明宏, 今泉 ちひろ, 齋藤 雅也, 小林 五十鈴, 藤島 眞澄, 藤島 直仁, 吉岡 智子, 後藤 明輝, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 63 ( 6 ) 523 - 529 2022年06月
非外傷性脾破裂(ASR)は悪性リンパ腫の致死的合併症である。血管内大細胞型B細胞リンパ腫(IVLBCL)に伴うASR(IVLBCL-ASR)の報告は過去に1例のみで,その機序は不明な点が多い。今回我々は,剖検所見からIVLBCL-ASRと診断した1例を報告する。症例は78歳男性。IVLBCLの精査中に出血性ショックのため突然死し,剖検所見で大量の血性腹水と脾破裂を認めた。全身の小血管内にCD20陽性大型異型リンパ球の浸潤を認めIVLBCLと診断し,腫瘍細胞浸潤は裂創部位を含めた脾被膜部ではわずかで脾臓中心部で著明で,脾中心部での腫瘍増殖による脾内圧亢進がASRの原因と考えられIVLBCL-ASRと確定診断した。患者は入院3ヵ月前に舌がんの精査目的で施行された18F-FDGPET/CT検査で右副腎に異常集積を認めており,病理所見では同部位に一致して腫瘍浸潤を認めた。IVLBCLの早期診断における18F-FDG PET/CT検査の有用性を再認識し,IVLBCLの進行に伴いASRの発症リスクが上昇することが示唆され,早期の全身化学療法の実施が重要であると考えられた。(著者抄録)
-
Fukuda N.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 89 ( 5 ) 609 - 616 2022年05月
-
ネフローゼ症候群に対するリツキシマブ維持療法の有効性と安全性の検討
加賀 一, 橋本 眞子, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 64 ( 3 ) 266 - 266 2022年05月
-
同種造血幹細胞移植後に粘膜類天疱瘡による難治性食道狭窄症を来した1例
藤田 菜々子, 山下 鷹也, 阿部 史人, 斎藤 綾乃, 北舘 明宏, 奈良 美保, 吉岡 智子, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 63 ( 5 ) 490 - 490 2022年05月
-
薬物モニタリングにより胃瘻からのベネトクラクス粉砕投与が安全に施行できた再発急性骨髄性白血病
佐藤 保奈実, 小林 敬宏, 藤田 菜々子, 吉岡 智子, 奈良 美保, 三浦 昌朋, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 63 ( 5 ) 489 - 489 2022年05月
-
Kaga H.
International Journal of Hematology ( International Journal of Hematology ) 115 ( 1 ) 129 - 134 2022年01月
Human herpesvirus-8 (HHV8)-positive, human immunodeficiency virus (HIV)-negative multicentric Castleman disease (MCD) is a rare and age-related lymphoproliferative disorder caused by cytokine storm. Rituximab treatment is currently recommended because B-cell depletion eliminates the primary reservoir for HHV8. We report the first case of effective rituximab treatment of a Japanese patient (an 87-year-old woman) with this disorder. Her inflammatory symptoms and lymphadenopathy improved after medium-dose steroid therapy, but these symptoms recurred during steroid tapering. After one course of rituximab therapy, she achieved sustained remission. HHV8-associated MCD should be considered as a possible diagnosis in HIV-negative patients with inflammatory symptoms and lymphadenopathy.
-
Matsuda Y.
Cancer Science ( Cancer Science ) 2022年
-
Takahashi N.
International Journal of Hematology ( International Journal of Hematology ) 2022年
-
Wataru Kuroki, Takahiro Kobayashi, Michinobu Umakoshi, Akihiro Kitadate, Chihiro Imaizumi, Masaya Saito, Isuzu Kobayashi, Masumi Fujishima, Naohito Fujishima, Tomoko Yoshioka, Akiteru Goto, Naoto Takahashi
[Rinsho ketsueki] The Japanese journal of clinical hematology ( 一般社団法人 日本血液学会 ) 63 ( 6 ) 523 - 529 2022年
Atraumatic splenic rupture (ASR) is a rare but fatal complication of malignant lymphoma. However, only one case of intravascular large B-cell lymphoma (IVLBCL)-related ASR (IVLBCL-ASR) has previously been reported, and the mechanism of IVLBCL-ASR is unknown. We present the case of a 78-year-old man who died unexpectedly and was diagnosed with IVLBCL-ASR pathologically by autopsy. A massive intraperitoneal hemorrhage and four lacerations on the splenic surface were discovered during the autopsy. CD20-positive lymphoma cells that infiltrated into small vessels were highly concentrated in the center of the spleen and were only slightly distributed in the lacerations on the splenic surface. Therefore, increased intrasplenic pressure due to lymphoma cell proliferation was identified as the cause of ASR. The patient had undergone 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for tongue cancer evaluation 3 months earlier, and positive uptake was found in the right adrenal gland, where lymphoma cell infiltration was confirmed by the autopsy. Our findings suggest that clinicians should be aware that the advanced stage of IVLBCL can cause fatal ASR via increased intrasplenic pressure. Therefore, early diagnosis and early treatment intervention are desirable to prevent the onset of IVLBCL-ASR, and 18F-FDG PET/CT is useful for the early diagnosis of IVLBCL.
-
Adult-onset Still's Disease during Pregnancy Treated with Tocilizumab
Imaizumi C.
Internal Medicine ( Internal Medicine ) 61 ( 20 ) 3137 - 3140 2022年
A 28-year-old woman exhibited a spiking fever, arthritis, and liver disfunction when she was 22 weeks pregnant. She was diagnosed with adult-onset Still's disease (AOSD). As her condition was resistant to corticosteroid therapy, tocilizumab (TCZ) was selected. The TCZ treatment was effective, and she delivered a healthy child while receiving TCZ treatment. Cases in which AOSD first arises during pregnancy are rare, and there have been no reports of TCZ treatment for AOSD being initiated during pregnancy. Although the safety of TCZ treatment during pregnancy has not been established, it may be effective against severe AOSD that develops during pregnancy.
-
Yuda J.
Cancer Medicine ( Cancer Medicine ) 12 ( 3 ) 2990 - 2998 2022年
-
Bortezomib-EPOCH併用療法により長期寛解が得られたHIV陰性精巣原発形質芽球性リンパ腫
藤島 崇嗣, 川端 良成, 道下 吉広, 北林 淳, 高橋 直人
臨床血液 ( 一般社団法人 日本血液学会 ) 63 ( 10 ) 1386 - 1391 2022年
<p>形質芽球性リンパ腫（PBL）は，HIV感染や免疫不全を背景に発症する稀なB細胞性リンパ腫である。今回，我々はHIV陰性精巣原発PBLに対し，bortezomib併用-EPOCH療法が著効し長期寛解が得られた症例を経験したので報告する。症例は86歳男性。免疫不全を伴う基礎疾患なし。急速に増大する右精巣腫瘍を認め，右高位精巣摘除術を施行した。摘除標本で形質細胞様異型リンパ球のびまん性増殖を認め，免疫組織化学染色で，CD38，CD138，CD56，λ，MUM1，EBER，MYC陽性であるが，CD20陰性，MIB1 index 90％であった。PET/CTで全身リンパ節腫脹を認めたが，骨髄および髄液浸潤はなく，PBL，臨床病期IIIE-A，IPI高中間リスクと診断した。髄注併用V-EPOCH療法を6コース施行し完全寛解が得られた。左精巣に予防的照射（計30 Gy）施行後，診断から2年半以上経過したが完全寛解を維持している。PBLは急速進行性で予後不良な疾患であるが，その稀少性から標準的治療は未確立である。精巣原発PBLに対し，髄注および局所照射を併用したV-EPOCH療法は，高齢者にも寛解と長期予後を期待できる有効な初期治療法の一つと考えられた。</p>
-
Takahashi N.
Cancer Medicine ( Cancer Medicine ) 2022年
-
Sato M.
Journal of X-Ray Science and Technology ( Journal of X-Ray Science and Technology ) 30 ( 4 ) 777 - 788 2022年
-
Early Pulmonary Rehabilitation with Neuromuscular Electrical Stimulation in a Patient with Acute Exacerbation of Rheumatoid Arthritis-associated Interstitial Lung Disease: A Case Report
OKURA Kazuki, TAKAHASHI Yusuke, HASEGAWA Kakeru, HATAKEYAMA Kazutoshi, SAITO Kimio, IMAIZUMI Chihiro, KAGA Hajime, TAKAHASHI Naoto
Physical Therapy Research ( 一般社団法人日本理学療法学会連合 ) advpub ( 0 ) 2022年
<p>Introduction: Early implementation of neuromuscular electrical stimulation (NMES) has been reported to prevent muscle atrophy and physical functional decline in patients requiring mechanical ventilation. However, its effect in patients with acute exacerbation of interstitial lung disease (ILD) remains unclear. We herein report our experience using the NMES combined with mobilization in a patient with an acute exacerbation of rheumatoid arthritis-associated ILD (RA-ILD) requiring mechanical ventilation. Case presentation: A 74-year-old man was admitted to the intensive care unit (ICU) and put on mechanical ventilation due to severe acute exacerbation of RA-ILD. Early mobilization and the NMES using a belt electrode skeletal muscle electrical stimulation system were started on day 7 of hospitalization (day 2 of ICU admission). The NMES duration was 20 min, performed once daily. The patient could perform mobility exercises on day 8 and could walk on day 16. We assessed his rectus femoris and quadriceps muscle thicknesses using ultrasound imaging, and found decreases of 4.5% and 8.4%, respectively, by day 14. On day 27, he could independently visit the lavatory, and the NMES was discontinued. He was instructed to start long-term oxygen therapy on day 49 and was discharged on day 63. His 6-minute walk distance was 308 m and his muscle thickness recovered to levels comparable to those at the initial evaluation at the time of discharge. Conclusion: Combining the NMES and mobilization started in the early phase and continued after ICU discharge was safe and effective in a patient with a severe acute exacerbation of RA-ILD.</p>
-
Takashiki R.
Japan Journal of Nursing Science ( Japan Journal of Nursing Science ) 2022年
-
Ovarian Follicular Lymphoma Diagnosed due to Hydronephrosis
Noguchi Shinsuke, Kimura Yuiko, Shibano Sumire, Ariake Chika, Iwasawa Takuya, Oyama Noriaki, Sato Hirokazu, Enomoto Katsuhiko, Takahashi Naoto
Japanese Journal of Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 293 - 298 2022年
<p>A 74-year-old woman presented with left lateral abdominal pain. Abdominal echography revealed left hydronephrosis and a pelvic mass. The patient underwent left adnexal resection of a suspected left ovarian tumor and was diagnosed with follicular lymphoma (FL) of clinical stage IIIA, grade 2. The patient was treated with rituximab-combined chemotherapy and achieved complete remission. The most common histological types of ovarian lymphoma are diffuse large B-cell lymphoma and Burkitt lymphoma, with FL being an extremely rare variant. We herein report a case of ovarian FL diagnosed as hydronephrosis. </p>
-
Ono T.
Cancer Science ( Cancer Science ) 114 ( 3 ) 995 - 1006 2022年
-
Fukushi Y.
British Journal of Clinical Pharmacology ( British Journal of Clinical Pharmacology ) 89 ( 5 ) 1695 - 1700 2022年
The effects of polymorphisms of ABCB1 and ABCG2 on the dose-adjusted plasma trough concentrations and cerebrospinal fluid (CSF)-to-plasma ratios of ponatinib were evaluated. Blood (C4 ) and CSF (CSF4 ) concentrations at 4 h after administration were determined. The median (95% confidence interval) CSF4 -to-C4 ratio of ponatinib in subjects homozygous for ABCB1 variants 1236T/T, 2677T/T + T/A or 3435T/T were significantly higher than that in a group of subjects with other genotypes (P = .026, .012 and .015, respectively). The median (95% confidence interval) CSF4 -to-C4 ratio of ponatinib in 4 patients with the combination of ABCB1 variants 1236T/T-2677T/T + T/A-3435T/T was 2.62% (1.42-3.42%); this ratio was significantly higher than that in subjects with other genotypes (1.08% [0.89-1.47%]; P = .006). The brain distribution of ponatinib was affected by ABCB1 polymorphisms and therefore seems to be modulated by P-glycoprotein at the blood-brain and blood-CSF barriers.
-
Abumiya M.
Scientific Reports ( Scientific Reports ) 11 ( 1 ) 6362 - 6362 2021年12月
The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C0) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C0 and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C0 and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P < 0.001 and r = - 0.315, P < 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = - 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate analyses, the SLC22A2 808G/G genotype, patient age, bosutinib C0 and second-line or later bosutinib were independent factors influencing the change rate of creatinine. Bosutinib elevated serum creatinine through organic cation transporter 2 (OCT2). We observed a 20% increase in serum creatinine with a median bosutinib C0 of 63.4-73.2 ng/mL. Periodic measurement of serum creatinine after bosutinib therapy is necessary to avoid progression to severe renal dysfunction from simple elevation of creatinine mediated by OCT2 following bosutinib treatment.
-
Ochi Y.
Nature Communications ( Nature Communications ) 12 ( 1 ) 2021年12月
-
Fujioka Y.
Cancers ( Cancers ) 13 ( 23 ) 2021年12月
-
ANCA関連腎炎の臨床病理学的重症度と好中球細胞外トラップ
齋藤 雅也, 齋藤 綾乃, 阿部 史人, 今泉 ちひろ, 加賀 一, 奈良 瑞穂, 高橋 直人
秋田腎不全研究会誌 ( 秋田腎不全研究会 ) 24 19 - 27 2021年11月
-
Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL
Kawano N.
International Journal of Hematology ( International Journal of Hematology ) 114 ( 4 ) 509 - 516 2021年10月
Although tyrosine kinase inhibitors (TKIs) play a crucial role in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), intolerance and resistance to TKIs have been serious problems. Due to a lack of research, the importance of the pharmacokinetics (PK) of TKIs is currently unclear. We examined the PK of the third-generation TKI ponatinib to monitor side effects and efficacy during treatments for one patient with CML-chronic phase (CP-CML) and two who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), one for CML-blastic crisis (BC-CML) and one for Ph + ALL. The patient with CP-CML was intolerant to multiple TKIs (dasatinib, nilotinib, imatinib, and bosutinib) and thus was switched to ponatinib (15 mg/day). The patients who received allo-HSCT for BC-CML and Ph + ALL received ponatinib (15 mg/day) as maintenance therapy. Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2–34.5), 33.1 (21.2–40.3) and 27.7 (13.6–29.9) in patients 1, 2, and 3, respectively. These values were around the target concentration (23 ng/ml). All patients are maintaining complete remission without side effects. In conclusion, serial evaluation of PK of ponatinib may yield meaningful information about its safety and efficacy.
-
Kitadate A.
Cancer Science ( Cancer Science ) 112 ( 9 ) 3645 - 3654 2021年09月
-
IGL/MYC再構成を有し、かつCD138の発現を伴うB細胞性リンパ芽球性白血病(Precursor B-lymphoblastic leukemia with IGL/MYC rearrangement and CD138 expression)
倉橋 保奈実, 山下 鷹也, 北舘 明宏, 道下 吉広, 川端 良成, 北林 淳, 松本 奈津美, 齋藤 雅也, 小林 敬宏, 藤島 直仁, 亀岡 吉弘, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS3 - 3 2021年09月
-
MYCの転座相手が非IgHと考えられるdouble hit lymphoma
安田 拓人, 亀岡 吉弘, 橋本 眞子, 藤岡 優樹, 斎藤 雅也, 鵜生川 久美, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 62 ( 9 ) 1417 - 1418 2021年09月
-
慢性リンパ性白血病に合併したmonoclonal immunotactoid glomerulopathy
齋藤 綾乃, 亀岡 吉弘, 小松田 敦, 鵜生川 久美, 今泉 ちひろ, 齋藤 雅也, 阿部 史人, 加賀 一, 奈良 瑞穂, 大谷 浩, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 63 ( 6-E ) 685 - 685 2021年09月
-
原発性マクログロブリン血症の経過観察中にMYD88陽性のびまん性大細胞型B細胞リンパ腫を発症した1例
高橋 照子, 倉橋 保奈実, 山下 鷹也, 齋藤 雅也, 小林 敬宏, 藤島 直人, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 62 ( 9 ) 1418 - 1418 2021年09月
-
皮膚T細胞性リンパ腫においてmiR-26aの抑制はIL-22の過剰発現を介して転移に寄与する
松田 悠佳, 池田 翔, 北舘 明宏, 高橋 祐斗, 阿部 滉, 阿部 史人, 高橋 直人, 涌井 秀樹, 田川 博之
日本癌学会総会記事 ( (一社)日本癌学会 ) 80回 [J14 - 5] 2021年09月
-
高腫瘍量濾胞性リンパ腫における治療前PET/CTを用いたTLGの予後予測因子としての有用性(Prognostic value of baseline total lesion glycolysis in high-tumor-burden follicular lymphoma)
黒木 航, 北舘 明宏, 山下 鷹也, 小林 敬宏, 池田 翔, 奈良 美保, 鵜生川 久美, 藤島 直仁, 吉岡 智子, 石山 公一, 亀岡 吉弘, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS1 - 1 2021年09月
-
再発難治性ホジキンリンパ腫に対する免疫チェックポイント阻害薬治療の後方視的解析(Retrospective analysis of ICI therapy for relapsed or refractory classical Hodgkin's lymphoma: THF26)
前田 峻大, 小宅 達郎, 久保 恒明, 高畑 武功, 玉井 佳子, 亀岡 吉弘, 高橋 直人, 宮入 泰郎, 村井 一範, 下瀬川 健二, 吉田 こず恵, 菅原 健, 猪倉 恭子, 福原 規子, 張替 秀郎, 佐藤 諒, 石澤 賢一, 田嶋 克史, 齊藤 宗一, 深津 真彦, 池添 隆之, 角田 三郎, 神林 裕行, 三田 正行, 森 甚一, 古和田 周吾, 伊藤 薫樹
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS2 - 2 2021年09月
-
成人初期前駆T細胞性急性リンパ性白血病の臨床的特徴と予後に関する後方視的研究 THF-24(Clinical features and prognosis of adult early T-cell precursor acute lymphoblastic leukemia: THF-24)
古川 瑛次郎, 大西 康, 遠宮 靖雄, 原崎 頼子, 深津 真彦, 池添 隆之, 亀岡 吉弘, 高橋 直人, 八田 俊介, 勝岡 優奈, 濱田 宏之, 村井 一範, 小宅 達郎, 伊藤 薫樹, 甲斐 龍幸, 助川 真純, 中嶌 真治, 柳谷 稜, 石澤 賢一, 山口 公平, 高橋 太郎, 張替 秀郎
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS3 - 5 2021年09月
-
Sasaki Y.
Journal of Immunology ( Journal of Immunology ) 207 ( 4 ) 1078 - 1086 2021年08月
Emergency granulopoiesis, also known as demand-adapted granulopoiesis, is defined as the response of an organism to systemic bacterial infections, and it results in neutrophil mobilization from reservoir pools and increased myelopoiesis in the bone marrow. Indirect and direct initiating mechanisms of emergency granulopoiesis have been hypothesized. However, the detailed mechanism of hyperactive myelopoiesis in the bone marrow, which leads to granulocyte left shift, remains unknown. In this study, we report that TLR4 is expressed on granulo-monocytic progenitors, as well as mobilized human peripheral blood CD34+ cells, which account for 0.2% of monocytes in peripheral blood, and ∼ 10% in bone marrow. LPS, a component of Gram-negative bacteria that results in a systemic bacterial infection, induces the differentiation of peripheral blood CD34+ cells into myelocytes and monocytes in vitro via the TLR4 signaling pathway. Moreover, CD34+ cells directly responded to LPS stimulation by activating the MAPK and NF-κB signaling pathways, and they produced IL-6 that promotes emergency granulopoiesis by phosphorylating C/EBPα and C/EBPβ, and this effect was suppressed by the action of an IL-6 receptor inhibitor. This work supports the finding that TLR is expressed on human hematopoietic stem and progenitor cells, and it provides evidence that human hematopoietic stem and progenitor cells can directly sense pathogens and produce cytokines exerting autocrine and/or paracrine effects, thereby promoting differentiation.
-
血液形態診断のためのケースカンファレンス Cryptic translocationを認めたPML-RARA陽性微細顆粒型急性前骨髄球性白血病
菊地 優子, 山下 鷹也, 小林 敬宏, 永沼 綾子, 齊藤 由紀子, 安保 綾奈, 荒井 杏子, 富谷 陽子, 高橋 直人, 植木 重治
日本検査血液学会雑誌 ( (一社)日本検査血液学会 ) 22 ( 2 ) 263 - 269 2021年07月
症例は50歳代男性。職場の健診にて白血球増多を指摘され当院紹介となった。受診の2日前より発熱、頭痛あり、また最近誘因無く四肢に紫斑が出現することを自覚していた。受診時の血液検査所見として、白血球著増、貧血、血小板減少、線溶亢進型播種性血管内凝固症候群を認めた。末梢血液像は、核網繊細で核形不整が顕著な単球様細胞で占められており、僅かにアズール顆粒が豊富な細胞やファゴット細胞を認めた。骨髄像は末梢血と同様の異常細胞で占められており、細胞表面マーカーでは、CD2、CD13、CD33、CD117、MPOが陽性、CD34、CD56、HLA-DRが陰性であった。染色体検査は正常核型であったが、遺伝子検査ではPML-RARA融合遺伝子を認めたことから、cryptic translocationを認めたPML-RARA陽性微細顆粒型急性前骨髄球性白血病の診断に至った。本症例のように線溶亢進型播種性血管内凝固症候群と白血病細胞の増多を認めるが、典型的な急性前骨髄球性白血病細胞をほとんど認めない場合は、微細顆粒型急性前骨髄球性白血病を鑑別に挙げ、全トランス型レチノイン酸による治療を遅滞なく行うことが重要である。(著者抄録)
-
抗がん剤起因性の肝類洞閉塞症候群に対し、デフィブロチドが著効したB細胞性リンパ腫
倉橋 保奈実, 山下 鷹也, 齋藤 雅也, 藤島 直仁, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 62 ( 4 ) 323 - 323 2021年04月
-
Mizuho Nara, Hajime Kaga, Masaya Saito, Fumito Abe, Ayano Saito, Chihiro Imaizumi, Atsushi Komatsuda, Hideki Wakui, Naoto Takahashi
Internal medicine (Tokyo, Japan) ( 一般社団法人 日本内科学会 ) 2021年03月
There are an increasing number of reports on the safe use of rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, in pregnant women with hematological malignancies or refractory autoimmune diseases. In 2014, the use of RTX for patients with complicated steroid-dependent nephrotic syndrome (SDNS) was approved in Japan. We herein report a woman with childhood-onset complicated SDNS due to focal and segmental glomerulosclerosis, who had two successful pregnancies while receiving RTX maintenance therapy. No adverse complications were observed during the pregnancies, and she delivered healthy newborns. This case suggested that RTX may be used safely in pregnant women complicated with SDNS.
-
Tocilizumab治療中に健常児を得た妊娠中期発症成人Still病
今泉 ちひろ, 阿部 史人, 加賀 一, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 高橋 直人
日本リウマチ学会北海道・東北支部学術集会抄録集 ( (一社)日本リウマチ学会-北海道・東北支部 ) 30回 54 - 54 2021年02月
-
Kobayashi T.
International Journal of Hematology ( International Journal of Hematology ) 2021年
国内共著
-
Hughes T.P.
Leukemia ( Leukemia ) 35 ( 6 ) 1631 - 1642 2021年
The ENESTop study evaluated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) in chronic phase who had received ≥3 years of tyrosine kinase inhibitor therapy and achieved sustained deep molecular response only after switching from imatinib to nilotinib. After 1-year nilotinib consolidation, 126 patients attempted TFR. At 48 weeks (primary analysis), 57.9% (73/126) were in TFR. In the present analysis at 5 years, 42.9% (54/126) were in TFR. Since the 48-week analysis, among patients who left the TFR phase, 58% (11/19) did not have a loss of molecular response and discontinued for other reasons. Of the 59 patients who reinitiated nilotinib upon loss of major molecular response (MMR) or confirmed loss of MR4, 98.3% regained MMR, 94.9% regained MR4, and 93.2% regained MR4.5. Overall adverse event rates decreased over the 5 years of TFR. In patients reinitiating nilotinib, there was a cumulative increase in cardiovascular events with longer nilotinib exposure. No disease progression or CML-related deaths were reported. Overall, these results confirm the durability and safety of TFR for patients receiving second-line nilotinib. Cardiovascular risk should be carefully managed, particularly when reinitiating treatment after TFR.
-
Kidoguchi K.
International Journal of Hematology ( International Journal of Hematology ) 2021年
-
長期間完全奏効を維持している高齢男性乳腺原発びまん性大細胞型B細胞リンパ腫
野口 晋佐, 斎藤 宏文, 佐々木 英人, 鎌田 収一, 榎本 克彦, 高橋 直人
臨床血液 ( 一般社団法人 日本血液学会 ) 62 ( 5 ) 341 - 345 2021年
<p>乳腺原発びまん性大細胞型B細胞リンパ腫（DLBCL）は稀な非ホジキンリンパ腫であり，殆どは女性に発症する。今回，自己免疫疾患や女性ホルモンの関与がない高齢男性に発症し，長期寛解が得られている胚中心B細胞型乳腺原発DLBCLを経験したので報告する。症例は65歳，男性。徐々に増大する右胸のしこりと右腋窩リンパ節腫脹を主訴として近医を受診した。右乳がんおよび右腋窩リンパ節転移疑いで針生検を行い悪性リンパ腫の診断となった。組織型確定に至らなかったため右乳腺腫瘤摘出術を施行され，乳腺原発DLBCL，胚中心B細胞型（Hans分類），臨床病期IIAの診断となり治療目的で当科紹介となった。R-CHOP療法6コースに加えCNS浸潤予防のため髄腔内注射を併用した。5年間完全寛解を維持している。稀ではあるが男性にも乳腺リンパ腫が生じ得るため組織学的早期診断とCNS再発予防への対応が重要である。</p>
-
Ozawa M.
Clinical and Experimental Nephrology ( Clinical and Experimental Nephrology ) 25 ( 11 ) 1193 - 1202 2021年
Background: Inhibitors of vascular endothelial growth factor (VEGF)-VEGF receptor 2 (VEGFR2) signaling, such as bevacizumab (Bmab), are used for the treatment of various advanced cancers. However, these inhibitors induce renal thrombotic microangiopathy (TMA). Recently, two European cohort studies showed a distinctive histopathological pseudothrombotic pattern different from TMA in Bmab-treated patients. Methods: We analyzed 9 renal biopsies from proteinuric cancer patients treated with VEGF-VEGFR2 inhibitors in our Japanese cohort. Clinical and laboratory features were also assessed in these patients. Results: All 9 patients had moderate to heavy proteinuria with normal or slightly elevated serum creatinine levels. On light microscopy, a patchy pattern of hemispherical/spherical lesions along glomerular capillary walls was a characteristic finding. On immunofluorescence microscopy, staining for immunoglobulins (IgM dominant) at varying intensities was observed mainly along glomerular capillary walls. Especially, hemispherical/spherical positive staining for immunoglobulins was a characteristic pattern. Immunohistochemical studies showed positive staining for immunoglobulins and negative staining for CD61-positive platelets in capillary hemispherical/spherical lesions and positive VEGF staining in podocytes. On electron microscopy, variably electron-dense material in dilated glomerular capillaries and partial effacement of podocyte foot processes were observed. After the withdrawal of VEGF-VEGFR2 inhibitors, proteinuria improved without any specific treatment in 8 patients. Conclusions: Histopathological findings in our patients treated with VEGF-VEGFR2 inhibitors were consistent with those observed in the recently described new form of Bmab-associated hyaline occlusive glomerular microangiopathy. This form should be considered in proteinuric cancer patients treated with VEGF-VEGFR2 inhibitors. Discontinuing VEGF-VEGFR2 inhibitors may lead to improvement of glomerular microangiopathy induced by these drugs.
-
The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment.
Kunio Hayashi, Kazuhiro Ikegame, Naoto Takahashi
Case reports in hematology 2021 5518727 - 5518727 2021年
In the era of tyrosine kinase inhibitor (TKI) treatment, its effectiveness in treating chronic myelogenous leukemia (CML) has been improved, ensuring the same prognosis as that of healthy people of the same age. However, there are some patients with de novo blast crisis that undergoes acute conversion from the time of diagnosis and does not respond to TKI treatment, especially in the older patients. Here, we present a case of an older patient with de novo lymphoid crisis who was first treated with a combination of TKI and chemotherapy, but it was difficult to maintain a durable deep molecular response (DMR). After he achieved major molecular response (MMR) or less, it was possible to suppress IS% to DMR by performing a combined treatment with interferon-α (IFN-α) and ponatinib. It is considered that DMR can be maintained by the combination of the two-way action of IFN-α, that is, the transfer of dormant CML stem cells to the cellcycle and the activation of a specific immune response to CML cells. This clinical result suggests the possibility of the re-emergence of IFN-α, which has been used a therapeutic drug in the past.
-
Kobayashi Takahiro, Kuroki Jun, Kobayashi Isuzu, Saito Masaya, Fujishima Masumi, Ubukawa Kumi, Fujishima Naohito, Kameoka Yoshihiro, Nanjo Hiroshi, Takahashi Naoto
International Journal of Myeloma ( (一社)日本骨髄腫学会 ) 11 ( 4 ) 27 - 31 2021年
-
Successful salvage therapy of D-PACE combined with pomalidomide in a patient with triple-class refractory secondary plasma cell leukemia
KOBAYASHI Takahiro, KUROKI Jun, KOBAYASHI Isuzu, SAITO Masaya, FUJISHIMA Masumi, UBUKAWA Kumi, FUJISHIMA Naohito, KAMEOKA Yoshihiro, NANJO Hiroshi, TAKAHASHI Naoto
International Journal of Myeloma ( 一般社団法人 日本骨髄腫学会 ) 11 ( 4 ) 27 - 31 2021年
<p>Novel agents have dramatically improved the prognosis of multiple myeloma (MM). However, the prognosis of MM resistant to several classes of novel agents and secondary plasma cell leukemia (sPCL) is poor. In such cases, cisplatin, doxorubicin, cyclophosphamide, and etoposide (PACE)-based regimens are considered in combination with dexamethasone, thalidomide, and bortezomib. Herein, we report the case of a 47-year-old patient with Bence Jones Protein (BJP)-λ-type MM, primary refractory to bortezomib, lenalidomide, and dexamethasone (VRd) therapy, which subsequently progressed to sPCL accompanied with the acquired 17p deletion. Although the patient was also refractory to daratumumab-based therapy (triple-class refractory MM), he was successfully treated with dexamethasone and pomalidomide with PACE (DP-PACE) therapy, and after three cycles, he achieved complete remission (CR) and bridged to allogeneic stem cell transplantation (SCT). To the best of our knowledge, this is the first report of DP-PACE regimen, which may be considered for patients with relapsed refractory MM as a bridge to SCT.</p>
-
有毛細胞白血病を疑うリンパ球増多症で発症し,細胞表面解析から診断に至った慢性NK細胞増多症の一例
齊藤由紀子, 小林敬宏, 小林敬宏, 鎌田幸子, 亀岡吉弘, 菊地優子, 永沼綾子, 富谷陽子, 高橋直人, 嵯峨知生, 嵯峨知生, 植木重治, 植木重治
日本検査血液学会雑誌 22 2021年
-
腎生検が治療の契機となった慢性リンパ球性白血病
今泉 ちひろ, 齋藤 綾乃, 北舘 明宏, 加賀 一, 齋藤 雅也, 奈良 瑞穂, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 62 ( 6 ) 580 - 580 2020年09月
-
Mori J.
International Journal of Hematology ( International Journal of Hematology ) 112 ( 1 ) 115 - 117 2020年07月
国内共著
-
Hino M.
International Journal of Hematology ( International Journal of Hematology ) 112 ( 1 ) 24 - 32 2020年07月 [査読有り]
国内共著
-
Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes.
Masahide Takeda, Shigeharu Ueki, Yohei Yamamoto, Miho Nara, Mineyo Fukuchi, Katsutoshi Nakayama, Yasufumi Omori, Naoto Takahashi, Makoto Hirokawa
Asia Pacific allergy 10 ( 3 ) e24 2020年07月
Hypereosinophilic syndrome, which is characterized by eosinophilia in the peripheral blood, often causes various organ disorders. Charcot-Leyden crystals are recognized features of various diseases, such as parasite infection and asthma, and are known to be classic hallmarks of eosinophilic inflammation. Our recent study revealed the mechanism of Charcot-Leyden crystal formation (i.e., galectin-10 crystallization), namely the involvement of eosinophil extracellular trap cell death, a nonapoptotic cell death. Here we report an autopsy case of a 57-year-old man who had died of hypereosinophilic syndrome. We found numerous eosinophil extracellular trap cell death-associated Charcot-Leyden crystals in the spleen and lymph nodes. Observation of abdominal lymph nodes by electron microscopy revealed eosinophil extracellular traps and free extracellular granules, which are characteristic of typical eosinophil extracellular trap cell death. In this case, we observed various sizes of Charcot-Leyden crystals that were stained with anti-galectin-10 immunofluorescent staining. Further studies are required to understand the pathophysiological roles of Charcot-Leyden crystals and these may lead to the development of novel therapeutic modalities for severe eosinophilic inflammation.
-
ループス腎炎V型におけるexostosin1(EXT1)/exostosin2(EXT2)の検討
今泉 ちひろ, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 小澤 政豊, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 62 ( 4 ) 268 - 268 2020年07月
-
ループス腎炎V型におけるextosin1(EXT1)/extosin2(EXT2)の検討
今泉 ちひろ, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 小澤 政豊, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 62 ( 4 ) 268 - 268 2020年07月
-
Ko T.K.
Blood ( Blood ) 135 ( 26 ) 2337 - 2353 2020年06月 [査読有り]
国際共著
-
PCd療法により維持透析を離脱し完全寛解を達成したpenta-refractory IgD-λ型多発性骨髄腫
池田 翔, 山田 雅浩, 黒木 航, 齋藤 綾乃, 藤岡 優樹, 鵜生川 久美, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 61 ( 4 ) 420 - 420 2020年04月
-
R-CHOP療法に奏効しているGCB typeのdouble expressor lymphoma(DEL)
山田 雅浩, 亀岡 吉弘, 鵜生川 久美, 齋藤 綾乃, 藤岡 優樹, 池田 翔, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 61 ( 4 ) 419 - 419 2020年04月
-
CD7-Positive Diffuse Large B-Cell Lymphoma Presenting as an Intranasal Tumor.
Kazuaki Teshima, Masaaki Kume, Yasushi Kawaharada, Takashi Saito, Ko Abe, Sho Ikeda, Hideaki Ohyagi, Megumi Zuguchi, Masashi Zuguchi, Yosuke Kubota, Yoshitaka Enomoto, Masahito Miura, Satsuki Takahashi, Masahiro Saito, Ken Saito, Naoto Takahashi
Case reports in hematology 2020 1514729 - 1514729 2020年
We report a case of a 74-year-old man with a cluster of differentiation (CD) 7-positive diffuse large B-cell lymphoma (DLBCL) in the right nasal cavity. Flow cytometry analyses showed CD7 and CD20 positivity in tumor cells. The patient received 6 cycles of R-CHOP plus local radiation therapy because positron emission tomography-computed tomography after R-CHOP revealed an intranasal lesion. The patient achieved complete remission (CR) after radiation therapy. The frequency of CD7-positive DLBCL is rare, and only 11 cases with follow-up of clinical course have been reported thus far. CR or partial response was noted in 8 of 11 cases after receiving rituximab combined with chemotherapy. In total, 9 of 12 cases involved the development of extranodal lesions, which occurred as an intranasal tumor in 3 cases. It is important to examine the clinical features by accumulation of further cases.
-
多発性骨髄腫においてCD38低発現はt(11;14)転座及びBCL2依存性に関連する
北舘明宏, 北舘明宏, 池田翔, 成田健太郎, 三浦大典, 寺尾俊紀, 津島隆史, 竹内正美, 高橋直人, 末永孝生
日本血液学会学術集会抄録(Web) 82nd 2020年
-
コントロール不良な高齢発症関節リウマチに後天性血友病を合併した一例
今泉 ちひろ, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 藤岡 優樹, 奈良 瑞穂, 郭 永梅, 奈良 美保, 小澤 政豊, 吉岡 智子, 小松田 敦, 高橋 直人
日本リウマチ学会北海道・東北支部学術集会抄録集 ( (一社)日本リウマチ学会-北海道・東北支部 ) 29回 86 - 86 2019年11月
-
B-ALL移植後再発症例におけるblinatumomabの治療反応性と免疫プロファイル
小林 敬宏, 鵜生川 久美, 藤島 眞澄, 亀岡 吉弘, 藤島 直仁, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 60 ( 11 ) 1596 - 1597 2019年11月
-
器質化肺炎と肥厚性硬膜炎にて発症した難治性IgG4関連疾患
阿部 史人, 斎藤 綾乃, 斎藤 雅也, 奈良 瑞穂, 郭 永梅, 奈良 美保, 吉岡 智子, 小松田 敦, 高橋 直人
日本リウマチ学会北海道・東北支部学術集会抄録集 ( (一社)日本リウマチ学会-北海道・東北支部 ) 29回 89 - 89 2019年11月
-
Yamashita T.
Bone Marrow Transplantation ( Bone Marrow Transplantation ) 54 ( 10 ) 1713 - 1716 2019年10月
-
ヘキソキナーゼ-2は低酸素誘導性オートファジーを促進し、多発性骨髄腫のプロテアソーム阻害薬抵抗性を誘導する(Hexokinase-2(HK2) promotes hypoxia-inducible autophagy, leading to proteasome inhibitor resistance in multiple myeloma)
池田 翔, 阿部 史人, 北舘 明宏, 高橋 直人, 田川 博之
日本癌学会総会記事 ( 日本癌学会 ) 78回 J - 1016 2019年09月
-
IgA-associated glomerulonephritis with MPGN-like patternの13症例
奈良 瑞穂, 澤村 昌人, 小松田 敦, 今泉 ちひろ, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 小澤 政豊, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 61 ( 6 ) 741 - 741 2019年08月
-
T細胞リンパ腫の腎浸潤で半月体性腎炎を来した1例
澤村 昌人, 畠山 卓, 斎藤 綾乃, 斎藤 雅也, 小松田 敦, 涌井 秀樹, 城 謙輔, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 61 ( 6 ) 725 - 725 2019年08月
-
被疑薬中止4週後のステロイド治療が奏功した薬剤性間質性腎炎
齋藤 雅也, 今泉 ちひろ, 齋藤 綾乃, 阿部 史人, 奈良 瑞穂, 小澤 政豊, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 61 ( 6 ) 734 - 734 2019年08月
-
ANCA関連腎炎の組織学的重症度と血清シトルリン化ヒストンH3濃度の関連についての検討
齋藤 雅也, 齋藤 綾乃, 阿部 史人, 加賀 一, 澤村 昌人, 奈良 瑞穂, 佐藤 隆太, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 61 ( 3 ) 347 - 347 2019年05月
-
IgA腎症における臨床的予後影響因子とOxford分類2016と日本分類2013の関連性についての検証
佐藤 隆太, 齋藤 雅也, 阿部 史人, 奈良 瑞穂, 奥山 慎, 小松田 敦, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 61 ( 3 ) 287 - 287 2019年05月
-
進行性ループス腎炎III型、IV型の現状と課題
阿部 史人, 齋藤 雅也, 奈良 瑞穂, 佐藤 隆太, 奥山 慎, 小松田 敦, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 61 ( 3 ) 345 - 345 2019年05月
-
Hirabayashi S.
Pediatric Blood and Cancer ( Pediatric Blood and Cancer ) 66 ( 5 ) e27612 2019年05月
-
池田 翔, 阿部 史人, 北舘 明宏, 小林 敬宏, 高橋 直人, 田川 博之
International Journal of Myeloma ( 日本骨髄腫学会 ) 9 ( 1 ) 83 - 83 2019年05月
-
好酸球増多疾患・好酸球性肺炎 著明な組織内シャルコー・ライデン結晶を認めた好酸球増多症候群患者
福地 峰世, 植木 重治, 山本 洋平, 奈良 美保, 今野 泰典, 面川 歩, 嵯峨 知生, 守時 由起, 大森 泰文, 高橋 直人, 廣川 誠
アレルギー ( (一社)日本アレルギー学会 ) 68 ( 4-5 ) 529 - 529 2019年05月
-
リンパ腫の病勢とANCAの増減に関連を認めたPR3-ANCA陽性CD5陽性びまん性大細胞型B細胞性リンパ腫
阿部 滉, 佐藤 隆太, 渡部 敦, 藤島 眞澄, 藤島 直仁, 亀岡 吉弘, 高橋 直人, 大田 泰徳
臨床血液 ( (一社)日本血液学会-東京事務局 ) 60 ( 4 ) 336 - 337 2019年04月
-
皮膚限局型IVLBCLで発症し、Asian variant様IVLBCLの臨床像で再発したaggressive B-cell lymphoma
高橋 凪, 郭 永梅, 阿部 史人, 山下 鷹也, 奈良 美保, 吉岡 智子, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 60 ( 4 ) 332 - 332 2019年04月
-
Guo Y.m.
Clinical Pharmacology in Drug Development ( Clinical Pharmacology in Drug Development ) 8 ( 3 ) 411 - 412 2019年04月
-
Membranous nephropathy with solitary polyclonal IgA deposition: A case report and literature review.
Masato Sawamura, Atsushi Komatsuda, Hajime Kaga, Ayano Saito, Tadashi Yasuda, Hideki Wakui, Kensuke Joh, Naoto Takahashi
Clinical nephrology. Case studies 7 60 - 65 2019年
A 60-year-old man presented with nephrotic syndrome (NS). Light microscopy of renal biopsy specimens showed minor glomerular abnormalities, while immunofluorescence microscopy revealed solitary polyclonal granular IgA deposition along the glomerular capillary walls. Electron microscopy showed small amounts of electron-dense deposits in the subepithelial area, but not in the mesangial area. In this patient, apparent underlying disease was not found during the 3-year follow-up, and low-dose prednisolone was effective in the treatment of NS. To our knowledge, there is only one case report of membranous nephropathy with clinicopathological features similar to our case.
-
Ogawa M.
British Journal of Haematology ( British Journal of Haematology ) 183 ( 5 ) 842 - 845 2018年12月
-
出血傾向で発症した第X因子欠乏を伴うALアミロイドーシス(Primary hepatic amyloidosis with factor X deficiency)
高橋 凪, 郭 永梅, 阿部 史人, 山下 鷹也, 奈良 美保, 吉岡 智子, 伊藤 行信, 吉田 誠, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1669 - 1669 2018年09月
-
ニボルマブ投与後に筋炎を発症したホジキンリンパ腫(Nivolumab-related myositis in Hodgkin's lymphoma)
郭 永梅, 小林 敬宏, 山下 鷹也, 奈良 美保, 鵜生川 久美, 渡部 敦, 藤島 眞澄, 藤島 直仁, 吉岡 智子, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1737 - 1737 2018年09月
-
ABCB1遺伝子多型は多発性骨髄腫患者におけるレナリドミドの薬物動態に影響を与える(ABCB1 polymorphism influence the pharmacokinetics of lenalidomide in patients with multiple myeloma)
小林 敬宏, 鐙屋 舞子, 赤嶺 由美子, 伊藤 史子, 志田 青慈, 三浦 昌朋, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1624 - 1624 2018年09月
-
CMLにおけるボスチニブの血中濃度と有害事象の関連性(Correlation of plasma concentration and adverse events of bosutinib in chronic myeloid leukemia)
三田 亜紀子, 鐙屋 舞子, 三浦 昌朋, 高橋 沙織, 吉岡 智子, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1703 - 1703 2018年09月
-
再発難治CLL/SLL, MCLに対するイブルチニブの有効性と安全性(The safety and efficacy of ibrutinib for relapsed/refractory MCL and CLL/SLL)
亀岡 吉弘, 北林 淳, 鵜生川 久美, 野口 晋佐, 大八木 秀明, 茂木 睦仁, 川端 良成, 小笠原 仁, 黒木 淳, 仁村 隆, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1602 - 1602 2018年09月
-
INCREASED MEAN PLATELET VOLUME (MPV) AS A POTENTIAL PREDICTOR OF THROMBOPOIETIC RECOVERY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHEMOTHERAPY
Yuko Kikuchi, Ayako Naganuma, Kana Haseyama, Kyoko Ono, Takeshi Kobayashi, Noriko Kobayashi, Ayumi Omokawa, Tomoo Saga, Shigeharu Ueki, Naoto Takahashi, Hironobu Shimizu, Makoto Hirokawa
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY ( WILEY ) 40 68 - 69 2018年09月
研究発表要旨（国際会議）
-
秋田県内の多施設調査による骨髄異形成症候群に対するアザシチジンの使用状況と安全性/有効性に関する検討(Azacitidine safety and efficacy in Myelodysplastic syndrome: A multicenter survey in Akita)
渡部 敦, 吉岡 智子, 伊藤 史子, 池田 翔, 郭 永梅, 奈良 美保, 藤島 眞澄, 藤島 直仁, 市川 善一, 中山 豊, 川端 良成, 北林 淳, 桑山 明久, 小笠原 仁, 井上 武, 茂木 睦仁, 仁村 隆, 三田 亜紀子, 道下 吉広, 波多野 善明, 伊藤 貢, 黒木 淳, 手島 和明, 大八木 秀明, 久米 正晃, 野口 晋佐, 鵜生川 久美, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1780 - 1780 2018年09月
-
解糖系遺伝子HK2は骨髄低酸素微小環境に存在する骨髄腫細胞に対する治療標的となりうる(A glycolytic gene HK2 as a therapeutic target of myeloma cells in hypoxic microenvironment)
池田 翔, 北舘 明宏, 阿部 史人, 高橋 直人, 田川 博之
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1611 - 1611 2018年09月
-
成人特発性血小板減少症におけるIGHV4-28/IGHJ4再構成由来IgG型B細胞抗原受容体の高発現(Overexpression of the rearranged IGHV4-28//IGHJ4 gene-derived IgG B-cell receptors in adult ITP)
藤島 直仁, 富樫 賢, 長谷川 諒, 渡部 健, 嵯峨 亜希子, 面川 歩, 嵯峨 知生, 植木 重治, 高橋 直人, 北浦 一孝, 鈴木 隆二, 廣川 誠
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1579 - 1579 2018年09月
-
腸炎を契機に発症した横紋筋融解に伴う急性腎障害
齋藤 雅也, 渡邊 春佳, 阿部 史人, 池田 翔, 奈良 瑞穂, 鵜生川 久美, 佐藤 隆太, 奥山 慎, 亀岡 吉弘, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 60 ( 6 ) 902 - 902 2018年08月
-
[Chronic myeloid leukemia: state-of-the-art management].
Takahashi N
[Rinsho ketsueki] The Japanese journal of clinical hematology ( 一般社団法人 日本血液学会 ) 59 ( 6 ) 747 - 754 2018年06月
<p>慢性期慢性骨髄性白血病の新たな治療目標である無治療寛解（treatment-free remission, TFR）とはチロシンキナーゼ阻害剤（tyrosine kinase inhibitor, TKI）により深い分子遺伝学的寛解（deep molecular response, DMR）に到達したのち，TKI治療を中止しても分子遺伝学的効果が維持される状態のことである。2017年のNCCNガイドラインでは「3年以上のTKI治療歴，2年以上のDMRの維持，TKI中止後半年間の月一回の分子遺伝学的モニタリングの実施とその後の定期的なモニタリングなど」の一定の条件を課して臨床試験以外でのTKI中止を世界で初めて許容した。本邦のガイドラインにおいても今後，臨床試験外のTFRが言及されると推測される。将来のTFRを成功させるため，少なくともDMRを達成し継続することが，TKI感受性を示す症例の課題である。</p>
-
Kobayashi T.
Annals of Hematology ( Annals of Hematology ) 97 ( 6 ) 1097 - 1099 2018年06月
-
特集 急性白血病の薬物療法のupdate ～最新の診断・治療戦略～ ８.治療薬物モニタリング
三浦昌朋, 高橋直人
医薬ジャーナル ( 医薬ジャーナル社 ) 54 ( 5 ) 1244 - 1248 2018年05月
-
治療への基礎的アプローチ 骨髄腫微小環境で発現上昇する解糖系遺伝子群の治療標的としての可能性
池田 翔, 北舘 明宏, 阿部 史人, 小林 敬宏, 高橋 直人, 田川 博之
International Journal of Myeloma ( 日本骨髄腫学会 ) 8 ( 2 ) 92 - 92 2018年05月
-
治療への基礎的アプローチ 骨髄腫微小環境で発現上昇する解糖系遺伝子群の治療標的としての可能性
池田 翔, 北舘 明宏, 阿部 史人, 小林 敬宏, 高橋 直人, 田川 博之
International Journal of Myeloma ( 日本骨髄腫学会 ) 8 ( 2 ) 92 - 92 2018年05月
-
ANCA関連血管炎における末梢血単核球でのToll-like receptors mRNA発現の検討
齋藤 綾乃, 加賀 一, 阿部 史人, 齋藤 雅也, 奈良 瑞穂, 佐藤 隆太, 奥山 慎, 小松田 敦, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 60 ( 3 ) 374 - 374 2018年04月
-
特発性膜性腎症における抗PLA2R抗体の経時的推移の検討
阿部 史人, 澤村 昌人, 齋藤 綾乃, 齋藤 雅也, 加賀 一, 小澤 政豊, 大谷 浩, 奥山 慎, 小松田 敦, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 60 ( 3 ) 370 - 370 2018年04月
-
特集 血液疾患における薬剤の副作用とその対策 １.チロシンキナーゼ阻害薬での対策１)末梢動脈閉塞性疾患(PAOD)(ニロチニブ)
吉岡智子, 高橋直人
血液フロンティア ( 医薬ジャーナル社 ) 28 ( 5 ) 673 - 679 2018年04月
-
著明な白血球増多を伴い急速な病状進行と多臓器障害を呈したG-CSF産生ALK陽性ALCL
渡部 敦, 阿部 史人, 奈良 美保, 鵜生川 久美, 藤島 眞澄, 吉岡 智子, 藤島 直仁, 亀岡 吉弘, 高橋 直人, 菅沢 邦江
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 4 ) 449 - 449 2018年04月
-
学会印象記 第59回 米国血液学会議(ASH2017)
池田翔, 髙橋直人
血液フロンティア ( 医薬ジャーナル社 ) 28 ( 4 ) 608 - 611 2018年03月
-
Tubulointerstitial nephritis with IgM-positive plasma cells
Takahashi N.
Journal of the American Society of Nephrology ( Journal of the American Society of Nephrology ) 28 ( 12 ) 3688 - 3698 2017年12月
-
BCL2、BCL6、MYC遺伝子転座を認めた治療抵抗性triple hit follicular lymphoma
池田 翔, 亀岡 吉弘, 斎藤 綾乃, 小林 五十鈴, 鵜生川 久美, 山下 鷹也, 奈良 美保, 郭 永梅, 渡部 敦, 藤島 眞澄, 藤島 直仁, 吉岡 智子, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 58 ( 12 ) 2473 - 2473 2017年12月
-
High-Throughput Sequencing of IgG B-Cell Receptors Reveals the Frequent Usage of the Rearranged IGHV4-28//IGHJ4 Gene in Primary Immune Thrombocytopenia in Adults
Naohito Fujishima, Masaru Togashi, Ryo Hasegawa, Ken Watanabe, Akiko Saga, Ayumi Omokawa, Tomoo Saga, Shigeharu Ueki, Naoto Takahashi, Kazutaka Kitaura, Ryuji Suzuki, Makoto Hirokawa
BLOOD ( AMER SOC HEMATOLOGY ) 130 2017年12月
研究発表要旨（国際会議）
0
-
Histone Deacetylase Inhibitors Downregulate CCR4 Expression and Decrease Mogamulizumab Efficacy in CCR4-Positive Mature T-Cell Lymphomas
Kitadate Akihiro, Ikeda Sho, Abe Fumito, Takahashi Naoto, Shimizu Norio, Matsue Kosei, Tagawa Hiroyuki
BLOOD 130 2017年12月
-
Hypoxia-Inducible KDM3A Addiction in Multiple Myeloma
Ikeda Sho, Kitadate Akihiro, Abe Fumito, Takahashi Naoto, Tagawa Hiroyuki
BLOOD 130 2017年12月
-
半月体を形成する糖尿病性腎症の臨床病理学的検討
齋藤 綾乃, 加賀 一, 齋藤 雅也, 阿部 史人, 奈良 瑞穂, 富樫 賢, 小松田 敦, 涌井 秀樹, 高橋 直人
秋田腎不全研究会誌 ( 秋田腎不全研究会 ) 20 43 - 47 2017年11月
腎生検で診断した糖尿病性腎症患者を対象とし、半月体形成を伴う群20例(男性16例、女性4例、36.0〜81.0歳)、伴わない群43例(男性31例、女性12例、18.5〜40.8歳)であった。腎生検時の年齢、BMI、血圧、尿蛋白、尿潜血、eGFR、HbA1c、総コレステロール値、C-reactive protein、糖尿病性網膜症の有無、降圧薬内服の有無、および腎予後について調査した。腎予後は透析導入をエンドポイントとした。臨床データは全ての項目で2群間に有意差を認めなかった。病理学的所見では糸球体病変がClass III(結節病変を伴う糸球体)の割合が半月体形成群で有意に高く、糸球体基底膜のIgG沈着も半月体形成群で有意に高かった。腎生存率は2群間で有意差を認めなかった。
-
Niioka T.
Therapeutic Drug Monitoring ( Therapeutic Drug Monitoring ) 39 ( 5 ) 514 - 521 2017年10月
-
Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes
Takenori Niioka, Naohito Fujishima, Maiko Abumiya, Takaya Yamashita, Kumi Ubukawa, Miho Nara, Masumi Fujishima, Naoto Takahashi, Masatomo Miura
THERAPEUTIC DRUG MONITORING ( LIPPINCOTT WILLIAMS & WILKINS ) 39 ( 5 ) 514 - 521 2017年10月
Background: Although voriconazole (VRCZ) is metabolized to VRCZ N-oxide principally by CYP2C19, VRCZ clearance is affected by multiple factors. In this study, we investigated the relationship between the CYP2C19 phenotype using the VRCZ-to-VRCZ N-oxide plasma concentration ratio (VRCZ/N-oxide) and demographic and clinical characteristics of Japanese patients taking VRCZ.
Methods: A total of 65 Japanese patients taking VRCZ for prophylaxis or treatment of fungal infection were enrolled in this study. Stepwise selection multiple linear regression analysis was performed to investigate the effect of factors on the VRCZ/N-oxide ratio.
Results: In patients not undergoing concurrent treatment with a drug influencing CYP2C19 activity (n = 54), the VRCZ/N-oxide ratio with definite thresholds for CYP2C19 genotypes, CYP2C19*1/ *1, *1/*2 + *1/*3 + *2/*17, and *2/*2 + *2/*3, was specifically identified in patients taking VRCZ (<0.48, >= 0.48, and <0.82 and >= 0.82). However, the VRCZ/N-oxide ratio could not be predicted based solely on the CYP2C19 genotype (R-2 = 0.053). The route of VRCZ administration, C-reactive protein concentration determined on the same day as VRCZ plasma concentration measurement, CYP2C19 extensive metabolizer, and patient age were independent factors influencing the VRCZ/N-oxide ratio (R-2 = 0.489, standard-ized regression coefficient = 0.385, 0.380, 20.231, and 0.231; P = 0.001, 0.001, 0.032, and 0.036, respectively).
Conclusions: It is possible to comprehensively evaluate CYP2C19 activity using the actual measured value of the VRCZ/N-oxide ratio in patients taking VRCZ. The predictive performance of the VRCZ/ N-oxide ratio was improved by including the route of administration, C-reactive protein level, and patient age in addition to the CYP2C19 genotype as predictive factors. -
Doki N.
Annals of Hematology ( Annals of Hematology ) 96 ( 9 ) 1517 - 1523 2017年09月
Post-transplant microbial diversity in the gastrointestinal tract is closely associated with clinical outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, little is known about the impact of the fecal microbiota before allo-HSCT. We analyzed fecal samples approximately 2 weeks before conditioning among 107 allo-HSCT recipients between 2013 and 2015. Microbial analysis was performed using 16S rRNA gene sequencing. Operational taxonomic unit-based microbial diversity was estimated by calculating the Shannon index. Patients were classified into three groups based on the diversity index: low (<2), intermediate (2, 3), and high (>3) diversity (18 (16.8%), 48 (44.9%), and 41 (38.3%) patients, respectively). There were no significant differences in the 20-month overall survival, cumulative incidence of relapse, and non-relapse mortality among three groups. The cumulative incidence of grade II to IV acute graft-versus-host disease (aGVHD) was similar among the three groups (low 55.6%; intermediate 35.4%; high 48.8%, p = 0.339, at day 100). Furthermore, we found no differences in the cumulative incidence of grade II to IV acute gastrointestinal GVHD among the three groups (low 38.9%; intermediate 21.3%; high 24.4%, p = 0.778, at day 100). Regarding the composition of microbiota before allo-HSCT, aGVHD patients showed a significantly higher abundance of phylum Firmicutes (p < 0.01) and a lower tendency for Bacteroidetes (p = 0.106) than non-aGVHD patients. Maintenance of Bacteroidetes throughout allo-HSCT may be a strategy to prevent aGVHD.
-
Takahashi N.
International Journal of Hematology ( International Journal of Hematology ) 106 ( 3 ) 398 - 410 2017年09月
This long-term follow-up of a completed phase 1/2 study assessed the safety and efficacy of bosutinib in Japanese Philadelphia chromosome-positive, chronic phase (CP) or advanced phase (ADV) chronic myeloid leukemia patients who were resistant/refractory or intolerant to prior tyrosine kinase inhibitor treatment. This analysis included 63 patients with a median bosutinib follow-up of 132 weeks (range 3aEuro'372). In the CP second-line (2L) cohort, the cumulative major cytogenetic response (MCyR) and major molecular response (MMR) rates throughout the study were 73 and 53%, respectively. In the CP third-line (3L) cohort, the cumulative MCyR and MMR rates throughout the study were 70 and 40%, respectively. Of the eight ADV patients, MCyR was attained or maintained by 50% of patients, and complete hematologic response was attained or maintained by 25% of patients. Progression-free survival rate and overall survival rate at 96 weeks were, respectively, 91 and 98% in CP2L, 88 and 100% in CP3L, and 33 and 50% in ADV patients. The most common adverse events (> 50%) reported were diarrhea (95%), nasopharyngitis (57%), and rash (57%). Bosutinib demonstrated durable efficacy and a manageable tolerability profile over long-term use in Japanese patients.
ClinicalTrials.gov: NCT00811070. -
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study
Tojo A.
International Journal of Hematology ( International Journal of Hematology ) 106 ( 3 ) 385 - 397 2017年09月
In this ongoing Phase 1/2 study (NCT01667133), we evaluated ponatinib and assessed its recommended dose in Japanese patients with chronic myeloid leukemia (CML) resistant/intolerant to dasatinib or nilotinib, or with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) resistant/intolerant to ≥1 tyrosine kinase inhibitor (TKI). The primary endpoints were safety of the recommended dose (Phase 1) and major cytogenetic response (MCyR) by 12 months in chronic-phase CML (CP-CML) patients or major hematologic response (MaHR) by 6 months in patients with advanced phase disease (Phase 2). MCyR was achieved/maintained by 12 months in 65% of CP-CML patients
MaHR was achieved by 6 months in 61% of patients with advanced phase disease. The most common nonhematologic grade 3/4 treatment-emergent adverse event (AE) was hypertension (37%)
common hematologic grade 3/4 AEs were thrombocytopenia (57%), neutropenia (34%), and leukopenia (26%). Overall, five (14%) patients experienced arterial occlusive events (AOEs)
no grade 5 AOEs were reported. The steady-state accumulation ratio of ponatinib (based on area under the curve) ranged from 2.6 (15 mg/day) to 1.3 (45 mg/day). In summary, ponatinib demonstrated efficacy in Japanese patients with CML and Ph+ALL resistant/intolerant to prior TKI treatment
safety data support a recommended starting dose of 45 mg/day in these patients. -
Nara M.
American Journal of Nephrology ( American Journal of Nephrology ) 46 ( 3 ) 187 - 194 2017年09月
-
T細胞リンパ腫においてHDAC阻害剤はCCR4発現を減少させモガムリズマブの作用を減弱させる
北舘 明宏, 池田 翔, 阿部 史人, 手島 和暁, 高橋 直人, 末永 孝生, 田川 博之
日本癌学会総会記事 ( 日本癌学会 ) 76回 E - 2025 2017年09月
-
低酸素環境における骨髄腫細胞の生存はH3K9脱メチル化酵素KDM3Aに依存する
池田 翔, 北舘 明宏, 阿部 史人, 高橋 直人, 田川 博之
日本癌学会総会記事 ( 日本癌学会 ) 76回 J - 3036 2017年09月
-
悪性リンパ腫におけるイノシトールリン脂質プロファイル
阿部 史人, 中西 広樹, 北舘 明宏, 池田 翔, 亀岡 吉弘, 高橋 直人, 佐々木 雄彦, 田川 博之
日本癌学会総会記事 ( 日本癌学会 ) 76回 P - 2236 2017年09月
-
早期LCDDに対してVRD療法が奏功した一例
齋藤 綾乃, 池田 翔, 伊藤 香里, 阿部 史人, 奈良 瑞穂, 奥山 慎, 涌井 秀樹, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 59 ( 6 ) 893 - 893 2017年09月
-
Ph陽性ALLに対するチロシンキナーゼ阻害剤の役割と臨床効果 (特集 急性リンパ芽球性白血病(ALL)の病態と診療 : 最近の展開)
山下 鷹也, 髙橋 直人
血液内科 = Hematology ( 科学評論社 ) 75 ( 3 ) 287 - 293 2017年09月
-
Honma M.
Applied Optics ( Applied Optics ) 56 ( 21 ) 5849 - 5856 2017年07月
-
同種造血幹細胞移植前にruxolitinibで脾腫のコントロールを行った多血症線維化期から移行した急性骨髄性白血病
藤島 眞澄, 藤島 直仁, 北舘 明宏, 郭 永梅, 渡部 敦, 鵜生川 久美, 奈良 美保, 吉岡 智子, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 58 ( 7 ) 743 - 748 2017年07月
症例は64歳女性(移植時年齢)。移植の7年前に真性多血症(JAK2 V617F変異陽性)と診断,2年前に脾腫が増悪しruxolitinibを開始した。汎血球減少のためruxolitinibを中止したところ,脾臓の増大と骨髄線維化を伴う白血化を認め,多血症後線維化期から移行した急性骨髄性白血病と診断した。寛解導入療法により完全寛解が得られたが,脾臓は季肋下8横指触知する状態であった。地固め療法2コース後にruxolitinibを再投与し,脾臓が縮小した時点で非血縁ドナーから末梢血幹細胞移植を行った。Ruxolitinibは移植前日まで継続した。Day 13に好中球生着が得られた後,withdrawal symptomと考えられる脾臓の再増大がみられたが一時的であった。脾腫は同種造血幹細胞移植における生着不全・移植関連死のリスク因子となるが,移植前の摘脾や照射は侵襲性が問題となる。Ruxolitinibは脾腫を非侵襲的に改善するため,移植前まで継続することにより,脾臓の縮小による生着率の向上が期待される。(著者抄録)
-
Tajima K.
Leukemia and Lymphoma ( Leukemia and Lymphoma ) 58 ( 6 ) 1509 - 1511 2017年06月
-
虚血性持続勃起症(Priapism)を契機に発見された急性骨髄性白血病とWaldenstrom's-macroglobulinemiaの重複例
永沼 綾子, 菊地 優子, 長谷山 佳菜, 小野 杏子, 小林 毅, 小林 則子, 北舘 明宏, 亀岡 吉弘, 高橋 直人, 廣川 誠
日本検査血液学会雑誌 ( (一社)日本検査血液学会 ) 18 ( 学術集会 ) S182 - S182 2017年06月
-
Yokoyama H.
International Journal of Hematology ( International Journal of Hematology ) 105 ( 5 ) 606 - 613 2017年05月
-
Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant.
Takashi Onaka, Naoto Takahashi, Masatomo Miura, Akihito Yonezawa
Clinical case reports 5 ( 5 ) 605 - 607 2017年05月
Nilotinib, a BCR-ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib-treated patients following transplant should be administered with careful pharmacokinetic monitoring because of its interaction with nilotinib.
-
Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma
Sho Ikeda, Akihiro Kitadate, Fumito Abe, Hirobumi Saitoh, Yoshihiro Michishita, Yoshiaki Hatano, Yoshinari Kawabata, Atsushi Kitabayashi, Kazuaki Teshima, Masaaki Kume, Naoto Takahashi, Hiroyuki Tagawa
Cancer Science ( Blackwell Publishing Ltd ) 108 ( 4 ) 641 - 652 2017年04月
Multiple myeloma (MM) is characterized by the accumulation of a population of malignant plasma cells within the bone marrow and its microenvironment. A hypoxic niche is located within the microenvironment, which causes myeloma cells to become quiescent, anti-apoptotic, glycolytic, and immature. Cell heterogeneity may be related to distinct gene expression profiles under hypoxic and normoxic conditions. During hypoxia, myeloma cells acquire these phenotypes by downregulating interferon regulatory factor 4 (IRF4), an essential transcription factor in myeloma oncogenesis. To identify essential microRNAs and their targets regulated under hypoxic conditions, we undertook microRNA and cDNA microarray analyses using hypoxia-exposed primary MM samples and myeloma cell lines. Under hypoxia, only miR-210 was highly upregulated and was accompanied by direct downregulation of an 18S rRNA base methyltransferase, DIMT1. This inverse expression correlation was validated by quantitative RT-PCR for primary MM samples. We further determined that DIMT1 has an oncogenic potential as its knockdown reduced tumorigenicity of myeloma cells through regulation of IRF4 expression. Notably, by analyzing gene expression omnibus datasets in the National Center for Biotechnology Information database, we found that DIMT1 expression increased gradually with MM progression. In summary, by screening for targets of hypoxia-inducible microRNA-210, we identified DIMT1 as a novel diagnostic marker and therapeutic target for all molecular subtypes of MM.
-
Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience
Ozawa M.
Clinical and Experimental Nephrology ( Clinical and Experimental Nephrology ) 21 ( 2 ) 212 - 227 2017年04月
Few studies have been conducted on the long-term prognosis of patients with amyloid light chain (AL) and amyloid A (AA) renal amyloidosis in the same cohort.
We retrospectively examined 68 patients with biopsy-proven renal amyloidosis (38 AL and 30 AA). Clinicopathological findings at the diagnosis and follow-up data were evaluated in each patient. We analyzed the relationship between clinicopathological parameters and survival data.
Significant differences were observed in several clinicopathological features, such as proteinuria levels, between the AL and AA groups. Among all patients, 84.2 % of the AL group and 93.3 % of the AA group received treatments for the underlying diseases of amyloidosis. During the follow-up period (median 18 months in AL and 61 months in AA), 36.8 % of the AL group and 36.7 % of the AA group developed end-stage renal failure requiring dialysis, while 71.1 % of the AL group and 56.7 % of the AA group died. Patient and renal survivals were significantly longer in the AA group than in the AL group. eGFR of > 60 mL/min/1.73 m(2) at biopsy and an early histological stage of glomerular amyloid deposition were identified as low-risk factors. A multivariate analysis showed that cardiac amyloidosis and steroid therapy significantly influenced patient and renal survivals.
Our results showed that heart involvement was the major predictor of poor outcomes in renal amyloidosis, and that the prognosis of AA renal amyloidosis was markedly better than that in previously reported cohorts. Therapeutic advances in inflammatory diseases are expected to improve the prognosis of AA amyloidosis. -
リツキシマブ治療を行った成人難治性ネフローゼ症候群7症例の検討
今泉 ちひろ, 加賀 一, 齋藤 雅也, 奈良 瑞穂, 富樫 賢, 小松田 敦, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 59 ( 3 ) 350 - 350 2017年04月
-
半月体形成糸球体を伴う膜性腎症の臨床病理学的検討
齋藤 雅也, 小松田 敦, 佐藤 隆太, 齋藤 綾乃, 阿部 史人, 加賀 一, 澤村 昌人, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 59 ( 3 ) 351 - 351 2017年04月
-
当科における特発性膜性腎症患者のHLA DQA1 sequence variants
加賀 一, 森 健介, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 面川 歩, 奥山 慎, 小松田 敦, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 59 ( 3 ) 237 - 237 2017年04月
-
当科開発ELISAとEuroimmune社ELISAによる当施設での特発性膜性腎症患者の抗phospholipase A2 receptor抗体の比較検討
加賀 一, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 山本 聡, 横田 伸一, 涌井 秀樹, 小松田 敦, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 59 ( 3 ) 268 - 268 2017年04月
-
糖尿病性腎症患者の末梢血単核球におけるToll-like receptor(TLR)2、4 mRNA発現と臨床組織学的検討
齋藤 綾乃, 加賀 一, 齋藤 雅也, 奈良 瑞穂, 小松田 敦, 涌井 秀樹, 高橋 直人
日本腎臓学会誌 ( (一社)日本腎臓学会 ) 59 ( 3 ) 292 - 292 2017年04月
-
移植非適応未治療多発性骨髄腫患者に対するLd療法およびレナリドミドの至適血漿中濃度の検討
小林 敬宏, 三浦 昌朋, 新岡 丈典, 鐙屋 舞子, 大八木 秀明, 篠原 良徳, 茂木 睦仁, 黒木 淳, 西成 民夫, 川端 良成, 北林 淳, 道下 吉広, 池田 翔, 志田 青慈, 吉岡 智子, 高橋 直人
International Journal of Myeloma ( 日本骨髄腫学会 ) 7 ( 1 ) 71 - 71 2017年04月
-
維持透析併用で自家移植を行い透析離脱できた多発性骨髄腫
荒井 岳史, 池田 翔, 新井 郷史, 今泉 ちひろ, 山下 鷹也, 北舘 明宏, 小林 五十鈴, 小林 敬宏, 奈良 美保, 郭 永梅, 鵜生川 久美, 渡部 敦, 藤島 直仁, 藤島 眞澄, 吉岡 智子, 亀岡 吉弘, 田川 博之, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 58 ( 4 ) 401 - 402 2017年04月
-
骨髄腫細胞において低酸素で上昇するコーディング・ノンコーディング遺伝子の網羅的探索とその機能解析
池田 翔, 北舘 明宏, 阿部 史人, 小林 敬宏, 高橋 直人, 田川 博之
International Journal of Myeloma ( 日本骨髄腫学会 ) 7 ( 1 ) 54 - 54 2017年04月
-
Komatsu N.
International Journal of Hematology ( International Journal of Hematology ) 105 ( 3 ) 309 - 317 2017年03月
-
DISTRIBUTION PATTERN OF GLOMERULAR IGG SUBCLASS DEPOSITS IN MEMBRANOUS NEPHROPATHY PATIENTS WITH CRESCENT FORMATION AND POSITIVE MPO-ANCA
Masaya Saitoh, Atsushi Komatsuda, Yuhta Oyama, Masato Sawamura, Masatoyo Ozawa, Hideki Wakui, Naoto Takahashi
RHEUMATOLOGY ( OXFORD UNIV PRESS ) 56 138 - 138 2017年03月
-
Komatsu N.
International Journal of Hematology ( International Journal of Hematology ) 105 ( 3 ) 2017年03月
-
ANCA-ASSOCIATED VASCULITIS COMPLICATING WITH LARGE VESSEL INVOLVEMENT AND HYPERTROPHIC PACHYMENINGITIS: REPORT OF AN AUTOPSY CASE AND REVIEW OF THE LITERATURE
Hajime Kaga, Atsushi Komatsuda, Masaya Saitoh, Mizuho Nara, Ayumi Omokawa, Masaru Togashi, Shin Okuyama, Hideki Wakui, Naoto Takahashi
RHEUMATOLOGY ( OXFORD UNIV PRESS ) 56 70 - 70 2017年03月
-
Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.
Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H, Tohoku Hematology Forum
International Journal of Hematology 105 ( 5 ) 606 - 613 2017年02月
-
Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan.
Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Harigae H, Ishida Y, Tohoku Hematology Forum
Leuk Lymphoma. 58 ( 6 ) 1509 - 1511 2017年01月
-
Teshima K, Ohyagi H, Kume M, Takahashi S, Saito M, Takahashi N
[Rinsho ketsueki] The Japanese journal of clinical hematology ( 一般社団法人 日本血液学会 ) 58 ( 11 ) 2227 - 2231 2017年
<p>79歳，男性。全身リンパ節腫脹で発症したT細胞受容体β鎖遺伝子再構成陽性，CD20陽性末梢性T細胞性リンパ腫（peripheral T-cell lymphoma, PTCL）, NOSに対してR-CHOP療法6コース施行し部分寛解を得た。2ヶ月後に早期再発を来たし，頸部リンパ節および皮膚の再生検でCD20陰転化を確認した。リンパ節病変はCCR4陽性であった。救援療法のGDP療法は奏効しなかった。皮膚病変に対してvorinostatを投与したが骨髄抑制のため中止，その後さらに皮膚病変は増悪した。増大した頸部リンパ節の生検を再度行ったところ，CD20再発現を認めた。CCR4陽性に対してmogamulizumabを投与したが病勢増悪し，再発から8ヶ月で死亡した。本例はCD20の発現がrituximab，vorinostat，gemcitabine治療の経過中に変化した興味深い症例と考えられる。</p>
-
Sawamura M.
Internal Medicine ( Internal Medicine ) 56 ( 6 ) 631 - 636 2017年
Objective We performed a prospective study to determine the efficacy and safety of denosumab on bone metabolic indices and bone mineral density (BMD) in 29 patients receiving long-term glucocorticoids (GCs) who had clinical risk factors for fracture. Methods Among these patients, 16 had systemic lupus erythematosus (SLE), 6 RA, 4 other autoimmune diseases, and 3 renal diseases. All patients received donosumab 60 mg at baseline and 6 months. Serum N-terminal cross-linked telopeptide of type I collagen (NTX) and bone-specific alkaline phosphatase (BAP) levels were measured as bone metabolic indices. BMD at the lumbar spine (LSBMD) and femoral neck (FNBMD) were measured using dual energy X-ray absorptiometry and expressed as a percentage of the young adult mean (%YAM). Results Denosumab therapy significantly reduced serum NTX and BAP levels from baseline after 12 months (from 19.2 to 13.9 nmol BCE/L
from 11.9 to 9.2 U/L, respectively). In 18 patients treated with bisphosphonates before the start of denosumab therapy, the improvements in the LSBMD and FNBMD values were 1.5%YAM/year and 1.1%YAM/year, respectively. The LSBMD and FNBMD values were both significantly higher 12 months after denosumab therapy (3.5%YAM/year and 3.0%YAM/year, respectively). The LSBMD gain was significantly higher after denosumab therapy than during bisphosphonate therapy. No fractures were observed in any patients during denosumab therapy. Conlusion Denosumab is effective and safe in preventing bone resorption and BMD loss in patients treated with long-term GCs for inflammatory diseases. This is the first study showing a significant increase in not only LSBMD but also FNBMD in GC-induced osteoporosis after denosumab therapy. -
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
Togasaki E.
Blood Cancer Journal ( Blood Cancer Journal ) 7 ( 4 ) e559 2017年
Although tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of chronic myeloid leukemia (CML), the ability of TKIs to eradicate CML remains uncertain and patients must continue TKI therapy for indefinite periods. In this study, we performed whole-exome sequencing to identify somatic mutations in 24 patients with newly diagnosed chronic phase CML who were registered in the JALSG CML212 study. We identified 191 somatic mutations other than the BCR-ABL1 fusion gene (median 8, range 1-17). Age, hemoglobin concentration and white blood cell counts were correlated with the number of mutations. Patients with mutations >= 6 showed higher rate of achieving major molecular response than thoseo6 (P = 0.0381). Mutations in epigenetic regulator, ASXL1, TET2, TET3, KDM1A and MSH6 were found in 25% of patients. TET2 or TET3, AKT1 and RUNX1 were mutated in one patient each. ASXL1 was mutated within exon 12 in three cases. Mutated genes were significantly enriched with cell signaling and cell division pathways. Furthermore, DNA copy number analysis showed that 2 of 24 patients had uniparental disomy of chromosome 1p or 3q, which disappeared major molecular response was achieved. These mutations may play significant roles in CML pathogenesis in addition to the strong driver mutation BCR-ABL1.
-
Abe F.
Oncotarget ( Oncotarget ) 8 ( 5 ) 7572 - 7585 2017年
Tumor suppressive microRNA (miR)-150 inhibits metastasis by combining with the C-C chemokine receptor 6 (CCR6) "seed sequence" mRNA of the 3'-untranslated region (3'-UTR) in advanced cutaneous T-cell lymphoma (CTCL). Because the histone deacetylase inhibitor (HDACI) vorinostat showed excellent outcomes for treating advanced CTCL, HDACIs may reduce the metastasis of CTCL by targeting miR-150 and/ or CCR6. To examine whether these candidate molecules are essential HDACI targets in advanced CTCL, we used the My-La, HH, and HUT78 CTCL cell lines for functional analysis because we previously demonstrated that their xenografts in NOD/Shi-scid IL-2γnul mice (CTCL mice) induced multiple metastases. We found that pan- HDACIs (vorinostat and panobinostat) inhibited the migration of CTCL cells and downregulated CCR6. The miRNA microarray analysis against CTCL cell lines demonstrated that these pan-HDACIs commonly upregulated 161 miRNAs, including 34 known tumor suppressive miRNAs such as miR-150. Although 35 miRNAs possessing the CCR6 "seed sequence" were included in these 161 miRNAs, miR-150 and miR-185-5p were downregulated in CTCL cells compared to in normal CD4+ T-cells. The transduction of 12 candidate miRNAs against CTCL cells revealed that miR-150 most efficiently inhibited their migration capabilities and downregulated CCR6. Quantitative reverse transcriptase-polymerase chain reaction demonstrated that miR-150 was downregulated in advanced but not early CTCL primary cases. Finally, we injected miR-150 or siCCR6 into CTCL mice and found that mouse survival was significantly prolonged. These results indicate that miR-150 and its target, CCR6, are essential therapeutic targets of pan-HDACIs in advanced CTCL with metastatic potential.
-
Masumi Fujishima, Naohito Fujishima, Akihiro Kitadate, Yongmei Guo, Atsushi Watanabe, Kumi Ubukawa, Miho Nara, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi
[Rinsho ketsueki] The Japanese journal of clinical hematology ( 一般社団法人 日本血液学会 ) 58 ( 7 ) 743 - 748 2017年
A 64-year-old woman was admitted to our hospital to undergo allogeneic stem cell transplantation. She was diagnosed with polycythemia vera with a JAK2 V617F mutation 7 years ago. She was administered ruxolitinib for splenomegaly two years prior to admission but this was discontinued because of progressive pancytopenia. One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. Although she achieved complete remission after induction therapy, 8-finger-breadth splenomegaly remained below the left costal margin. Ruxolitinib was re-administered following two courses of consolidation therapy. She underwent unrelated peripheral blood stem cell transplantation. Ruxolitinib was administered until the day before transplantation, and the spleen was palpated in 4-finger breadth below costal arc. Neutrophil engraftment was achieved 13 days after transplantation. In allogeneic stem cell transplantation, splenomegaly is one of the risk factors for engraftment failure and/or therapy-related mortality. Hence, a smaller spleen size can theoretically improve the outcome after transplantation. The administration of ruxolitinib prior to transplantation may have contributed to engraftment with a non-invasive reduction in the size of the spleen.
-
TAFRO Syndrome with Bilateral Adrenal Hemorrhage
Ito F, Kameoka Y, Nara M, Ubukawa K, Fujishima M, Yoshioka T, Fujishima N, Takahashi N
Nihon Naika Gakkai Zasshi. ( 日本内科学会 ) 106 ( 2 ) 288 - 294 2017年
-
Nara M.
Internal Medicine ( Internal Medicine ) 56 ( 10 ) 1247 - 1252 2017年
Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis/Renal failure, and Organomegaly (TAFRO) syndrome is a recently described systemic inflammatory disorder characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly. It has an acute or subacute onset of unknown etiology, although some pathological features resemble those of multicentric Castleman disease. We here report two cases of TAFRO syndrome. The symptoms and pathological findings in these cases met the 2015 diagnostic criteria. Our cases showed high serum procalcitonin levels, suggesting bacterial infection as an onset trigger. In addition, Case 1 is the first case complicated with adrenal hemorrhaging. Case 2 is the second case of tocilizumab-resistant TAFRO syndrome successfully treated with rituximab.
-
伊藤 史子, 亀岡 吉弘, 奈良 美保, 鵜生川 久美, 藤島 眞澄, 吉岡 智子, 藤島 直仁, 高橋 直人
日本内科学会雑誌 ( 一般社団法人 日本内科学会 ) 106 ( 2 ) 288 - 294 2017年
<p>48歳，男性．発熱，全身性浮腫とリンパ節腫脹で発症し，炎症反応高値，副腎出血，血小板減少，骨髄線維化を認めた．副腎出血による副腎不全を合併した悪性リンパ腫を疑ったが，リンパ節生検にてCastleman病の病理所見と一致し，多彩な臨床症状と検査所見を総合的に判断し，TAFRO症候群と診断した．Prednisolone（PSL）により症状の改善がみられた．頻度は稀だが，本症例のような多彩な臨床症状と特徴的な検査所見を示す場合，TAFRO症候群を念頭に置く必要がある．</p>